Drug delivery methods targeting lymphatic system
Microneedle devices with nanotopography enable targeted drug delivery to specific lymph nodes in the lymphatic system, addressing the challenge of selective treatment and reducing systemic exposure, thus enhancing treatment efficacy for conditions like cancer metastasis and inflammatory diseases.
Patent Information
- Application Number
- JP2024139013
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-05-31
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing drug delivery methods struggle to selectively target and treat specific lymph nodes in the lymphatic system, particularly for conditions like cancer metastasis and inflammatory diseases, while minimizing systemic exposure and side effects.
A method using microneedle devices with nanotopography to administer therapeutic agents directly to specific lymph nodes or regions of the lymphatic system, allowing for targeted delivery through multiple locations on the skin, including proximate lymphatic vessels and capillaries, to achieve cumulative or sequential therapeutically effective doses.
Enhances the ability to treat lymphatic system-related conditions by providing targeted drug delivery to specific lymph nodes, reducing systemic exposure, and minimizing side effects, thereby improving treatment efficacy and patient outcomes.
Smart Images

Figure 2024159854000005 
Figure 2024159854000006 
Figure 2024159854000007
Abstract
Description
[Technical field]
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 678,601, filed May 31, 2018, U.S. Provisional Patent Application No. 62 / 678,592, filed May 31, 2018, and U.S. Provisional Patent Application No. 62 / 678,584, filed May 31, 2018.
[0002] The field of the disclosure relates generally to the administration of medicines to a patient's lymphatic system using a fluid delivery device that allows for targeting of specific lymph nodes. More particularly, the disclosure relates to the administration of medicines to a patient suffering from a medical condition that can be improved by administration of medicines to the patient's lymphatic system. [Background technology]
[0003] The lymphatic system plays a vital role in transporting fluids and particulate matter throughout the body. It includes several lymphatic organs (e.g., the spleen and thymus) in addition to lymph nodes, lymphatic vessels, and lymphatic capillaries. Lymphatic vessels transport lymph fluid unidirectionally throughout the body by either superficial or deep lymphatic vessels (i.e., the lymphatic vasculature). Drainage begins at blind-ended capillaries that gradually develop into lymphatic vessels. These lymphatic vessels then pass through several lymph nodes. Lymph nodes contain both T and B lymphocytes, as well as other cells associated with the immune system. Antigens and other foreign particles are filtered in the lymph nodes. Lymphatic vessels eventually end up in either the right lymphatic trunk, which empties into the right internal jugular vein, or the thoracic duct, which empties into the subclavian vein. The lymphatic vessels are a one-way system in which lymph (also called lymph) is eventually returned to the patient's circulatory system.
[0004] Large proteins and certain cells (lymphocytes) pass through plasma into tissue fluids, and the return of these essential components to the blood circulation is an important function of lymph (i.e., the fluid of the lymphatic system). Lymph also plays an important role in transporting chylomicrons, products of lipid digestion in the digestive tract, into the blood circulation.
[0005] A number of devices have been developed for transdermal drug delivery using microneedle assemblies or arrays. Microneedle assemblies reduce the amount of pain felt by the patient compared to larger conventional needles. Furthermore, subcutaneous (and often intramuscular) delivery of drugs using conventional needles serves to deliver large amounts of drug at once, thereby resulting in a spike in the bioavailability of the therapeutic agent. While this is not a major issue for some medicines, many medical conditions benefit from a steady-state concentration of the active therapeutic agent lasting for an extended period of time. Transdermal delivery devices are capable of administering the drug at a substantially constant rate for an extended period of time. Some devices are capable of delivering the drug directly to the lymphatic system of the patient. One such device is the Sofusa™ drug delivery platform available from Sorrento Therapeutics, Inc.
[0006] Metastasis is believed to be the direct or indirect cause of more than 90% of all cancer deaths, and the lymphatic system plays a large role in cancer metastasis. Malignant cells can enter the lymphatic system and be captured by lymph nodes, where secondary tumors can be generated. Eventually, the entire lymphatic chain can be involved. The lymphatic system is also often involved in the spread of tumors to other parts of the body (i.e., metastasis). As a result, there is a need for methods to prevent or reduce the spread of malignant cells through the lymphatic system. Increased lymphatic vessel density often occurs with malignant disease due to the induction of lymphangiogenesis. This increases the likelihood that invasive cancer cells will enter the lymphatic system, which in turn will cause tumors to spread from local lymph nodes throughout the patient's body, resulting in poor patient outcomes. Because lymph nodes are often the first stop for spreading cancer cells, it is important to be able to selectively target and treat these cells in order to most effectively treat the patient. Thus, a need exists to be able to selectively deliver pharmaceutical agents to specific lymph nodes to treat and / or kill malignant cells.
[0007] Tumor necrosis factor alpha (TNF-α) has become an important therapeutic target in association with a wide variety of medical conditions, including rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis (UC), and Crohn's disease. Several drugs that specifically target TNF-α have been approved by the FDA, including adalimumab (Humira®), adalimumab-atto (Amjevita®, biosimilar of Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), etanercept-szzs (Ereizi®, biosimilar of Enbrel®), golimumab (Simponi®, Simponi Aria®), infliximab (Remicade®), and infliximab-dyyb (Inflectra®, biosimilar of Remicade®), but literally dozens of clinical trials are ongoing for either new therapeutic agents or expanding the use of currently approved agents. Known side effects of TNF-α inhibitors include headache, heartburn, nausea, vomiting, allergic reactions, and muscle weakness. Because TNF-α plays an important role in the immune system, altering TNF-α activity can make patients more susceptible to secondary infections or some cancers. Thus, there is a need to develop dosing regimens or methods that maintain a therapeutically effective dose of a therapeutic agent in a patient while simultaneously reducing the patient's systemic exposure to the therapeutic agent. Summary of the Invention [Means for solving the problem]
[0008] Thus, the following embodiments are provided.
[0009] Embodiment 1 is a method for administering a therapeutic agent to the lymphatic system of a patient, comprising: placing a first medical device including a plurality of microneedles on the patient's skin at a first location proximate a first position under the patient's skin, the first location proximate a lymphatic vessel and / or lymphatic capillary that drains into a right lymphatic trunk, the microneedles of the first medical device having a surface including a nanotopography; placing a second medical device comprising a plurality of microneedles on the patient's skin at a second location proximate a second location under the patient's skin, optionally wherein the first and second medical devices are the same device, the second location proximate a lymphatic vessel and / or lymph capillaries draining into the thoracic duct, and wherein the microneedles of the second medical device have a surface comprising nanotopography; inserting a plurality of microneedles of a first medical device into a patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a first location; inserting a plurality of microneedles of a second medical device into a patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a second location; and administering a first dose of a therapeutic agent to a first location via the microneedles of a first medical device and administering a second dose of a therapeutic agent to a second location via the microneedles of a second medical device. The method includes:
[0010] Embodiment 2 is a method according to embodiment 1, wherein the administration of the first dose and the administration of the second dose are simultaneous.
[0011] Embodiment 3 is a method according to any one of embodiments 1 or 2, wherein the administration of the first dose and the administration of the second dose overlap in time.
[0012] Embodiment 4 is a method according to any one of embodiments 1-3, wherein the administration of the first dose and the administration of the second dose are sequential.
[0013] Embodiment 5 is a method according to any one of embodiments 1-4, wherein the first and second medical devices are different devices.
[0014] Embodiment 6 is a method according to embodiment 4, wherein the first and second medical devices are the same device.
[0015] Embodiment 7 is a method according to any one of embodiments 1-6, wherein administration of both doses cumulatively provides a therapeutically effective amount of the therapeutic agent.
[0016] Embodiment 8 is a method according to any one of embodiments 1-7, wherein the first location and the second location are on different limbs of the patient.
[0017] Embodiment 9 is a method according to any one of embodiments 1-8, wherein the first location and the second location are each independently proximate a hand or foot of the patient.
[0018] Embodiment 10 is a method according to any one of embodiments 1-9, wherein one of the first location or the second location is on the patient's right arm or right leg, and the other location is on the patient's left arm or left leg.
[0019] Embodiment 11 is a. placing a third medical device including a plurality of microneedles on the patient's skin at a third location proximate a third location under the patient's skin, the third location proximate a lymphatic vessel and / or lymphatic capillaries; b. inserting a plurality of microneedles of a third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a third location; and c. Administering a third dose of said therapeutic agent via a third medical device. Further comprising: d. the third location is different from the first location and the second location; e. the third location is different from the first location and the second location; The method according to any one of the first to tenth embodiments.
[0020] Embodiment 12 is the method according to embodiment 11, wherein the first location, the second location and the third location are on different limbs of the patient.
[0021] Embodiment 13 is a method for administering a therapeutic agent to a subject, the method comprising the steps of: administering a therapeutic agent to a region of the lymphatic system that initially drains a different lymph node; and The method according to embodiment 11 or 12, wherein the draining lymph nodes are selected from the group of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, extra-aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes.
[0022] Embodiment 14 is a. placing a fourth medical device including a plurality of microneedles on the patient's skin at a fourth location proximate a fourth location under the patient's skin, the fourth location being proximate a lymphatic vessel and / or lymphatic capillary; b. inserting a plurality of microneedles of a fourth medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a fourth location; and c. Administering a fourth dose of said therapeutic agent via a fourth medical device. Further comprising: d. the first location, the second location, the third location, and the fourth location are on different limbs of the patient; The method according to any one of the embodiments 11 to 13.
[0023] Embodiment 15 is the method according to embodiment 14, wherein the first dose and the second dose are administered simultaneously, and the third dose and the fourth dose are administered simultaneously, wherein the administration start time of the first dose and the second dose is different from the administration start time of the third dose and the fourth dose, and there is a certain amount of time between the administration start times of the doses.
[0024] Embodiment 16 is
[0025] a. The third location drains into the right lymphatic trunk,
[0026] b. The method according to either embodiment 14 or 15, wherein the fourth location flows into the thoracic duct.
[0027] Embodiment 17 is the method of embodiment 16, wherein the first location and the third location on the patient's skin are different from one another, the first location and the third location are different from one another, and the first location and the third location are selected such that the therapeutic agent is administered to areas of the lymphatic system that initially drain into different lymph nodes.
[0028] Example 18 is the method of Example 17, wherein the second location and the fourth location on the patient's skin are different from one another, and the second and fourth portions of the lymphatic system are different from one another, and the second location and the fourth location are selected such that the therapeutic agent is administered to areas of the lymphatic system that initially drain into different lymph nodes.
[0029] Embodiment 19 is a method according to any one of embodiments 1-18, wherein the administration of the first dose of the therapeutic agent and the administration of the second dose of the therapeutic agent overlap in time.
[0030] Embodiment 20 is a method for administering a therapeutic agent to the lymphatic system of a patient, comprising: placing a first medical device including a plurality of microneedles on the patient's skin at a first location proximate a first position under the patient's skin, the first location proximate a lymphatic vessel and / or lymphatic capillary that drains into a right lymphatic trunk, the microneedles of the first medical device having a surface including a nanotopography; placing a second medical device comprising a plurality of microneedles on the patient's skin at a second location proximate a second location under the patient's skin, the second location being proximate a lymphatic vessel and / or lymphatic capillaries draining into the thoracic duct, the microneedles of the second medical device having a surface comprising nanotopography, and optionally the first and second medical devices being the same medical device; inserting a plurality of microneedles of a first medical device into a patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a first location; inserting a plurality of microneedles of a second medical device into a patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a second location; administering a first dose of a therapeutic agent to a first location via a microneedle of a first medical device; and Administering a second dose of a therapeutic agent to a second location via the microneedles of a second medical device. Including, The method wherein the administration start times of the first dose and the second dose are different and separated by a fixed time.
[0031] Embodiment 21 is a method according to embodiment 20, wherein the period of time is at least 4, 6, 8, 10, 12, 16, 24, 36, 48 or 72 hours.
[0032] Embodiment 22 is a method according to any one of embodiments 20 or 21, wherein the first dose, the second dose, or the first and second doses together comprise a therapeutically effective dose.
[0033] Embodiment 23 is a method according to any one of embodiments 20-22, wherein the first dose and the second dose are therapeutically effective doses.
[0034] Embodiment 24 is a. placing a third medical device comprising a plurality of microneedles on the patient's skin at a third location proximate a third location under the patient's skin, the third location proximate a lymphatic vessel and / or lymphatic capillaries, and the microneedles of the third medical device having a surface comprising nanotopography; b. inserting a plurality of microneedles of a third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a third location; and c. administering a third dose of a therapeutic agent to a third location via a microneedle of a third medical device. Further comprising: d. The administration start times of the first dose, the second dose, and the third dose are separated by a fixed time, e. the first location, the second location, and the third location are located on different limbs of the patient; The method according to embodiments 20 to 23.
[0035] Embodiment 25 is a. placing a third medical device comprising a plurality of microneedles on the patient's skin at a third location proximate a third location under the patient's skin, the third location proximate a lymphatic vessel and / or lymphatic capillaries, and the microneedles of the third medical device having a surface comprising nanotopography; b. inserting a plurality of microneedles of a third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a third location; and c. administering a third dose of a therapeutic agent to a third location via a microneedle of a third medical device. Further comprising: d. the administration start times of the first dose, the second dose and the effective dose are separated by a fixed time, e. the first location and the third location are different and selected such that the therapeutic agent is administered initially to areas of the lymphatic system that drain into different lymph nodes; The method according to embodiments 20 to 23.
[0036] Embodiment 26 is a method according to any one of embodiments 24 or 25, wherein the first dose, the second dose, the third dose, or a combination of any two or more thereof, constitutes a therapeutically effective dose.
[0037] Embodiment 27 is a method according to any one of embodiments 24-26, wherein the first dose, the second dose, and the third dose are therapeutically effective doses.
[0038] Embodiment 28 is a method according to any of embodiments 24-27, wherein the first location and the third location initially drain to different lymph nodes.
[0039] Embodiment 29 is a. placing a fourth medical device comprising a plurality of microneedles on the patient's skin at a fourth location proximate a fourth location under the patient's skin, the fourth location being proximate a lymphatic vessel and / or lymphatic capillary, the microneedles of the fourth medical device having a surface comprising nanotopography; b. inserting a plurality of microneedles of a fourth medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate a fourth location; and c. administering a fourth therapeutically effective dose of a therapeutic agent to the fourth location via the microneedles of a fourth medical device. Further comprising: d. The administration start times of the first dose, the second dose, the third dose, and the fourth dose are separated by a fixed time, e. the third level lymphatic duct and / or lymphatic capillaries drain into the right lymphatic trunk, and the fourth level lymphatic duct and / or lymphatic capillaries drain into the thoracic duct; f. the first location and the third location are different and selected to initially administer the therapeutic agent to areas of the lymphatic system that drain into different lymph nodes; g. the second location and the fourth location are different and selected such that the therapeutic agent is administered to an area of the lymphatic system that initially drains a different lymph node; The method according to any one of embodiments 24 to 28.
[0040] Embodiment 30 is a method according to embodiment 29, wherein the first dose, the second dose, the third dose, the fourth dose, or a combination of any two or more thereof, constitutes a therapeutically effective dose.
[0041] Embodiment 31 is a method according to embodiment 29 or 30, wherein the first dose, the second dose, the third dose and the fourth dose are therapeutically effective doses.
[0042] Embodiment 32 is a method according to any one of embodiments 1 to 31, wherein the first and second locations provide delivery to lymphatic capillaries and / or lymphatic vessels that drain into different lymph nodes.
[0043] Embodiment 33 is a method according to any one of embodiments 1 to 32, wherein the lymph nodes are selected from the group of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, extra-aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof.
[0044] Embodiment 34 is the method of any one of embodiments 1-33, wherein the first location is a first arm and the second location is selected from an opposing leg or arm of the patient's body.
[0045] Embodiment 35 is the method of any one of embodiments 1-34, wherein the therapeutic agent is an immunosuppressant.
[0046] Embodiment 36 is the method of any one of embodiments 1-35, wherein the therapeutic agent is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, ustekinumab, rituximab, secukinumab, omalizumab, natalizumab, ixekizumab, obinutuzumab, rituximab / hyaluronidase human, or a biosimilar or bioequivalent of any of the foregoing.
[0047] Embodiment 37 is the method of any one of embodiments 1 to 36, wherein the therapeutic agent is an anti-CTLA-4 antibody.
[0048] Embodiment 38 is a method for preventing or reducing metastasis of a cancer in a patient, comprising: locating at least one lymph node of the patient that is interposed in the lymphatic system between the solid cancer tumor and a draining duct; placing a medical device including a plurality of microneedles on the patient's skin proximate to a first location under the patient's skin, the first location being located between an intervening lymph node and a solid cancer tumor, the first location being proximate to a lymphatic vessel and / or lymphatic capillary of the patient's lymphatic system, the microneedles having a surface including nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to a first location; and administering to the first location via the plurality of microneedles a therapeutically effective amount of an anti-CTLA-4 antibody effective to prevent or reduce metastasis of the solid cancer tumor. The method includes:
[0049] Embodiment 39 is a method for preventing or reducing metastasis of a cancer in a patient, comprising: locating a solid cancer tumor in the patient and locating at least one lymph node in the patient that is interposed in the lymphatic system between the solid cancer tumor and the draining lymphatic system; placing a medical device including a plurality of microneedles on the patient's skin at a first location on the patient's skin proximate to lymphatic capillaries and / or lymphatic vessels that drain to an intervening lymph node, the microneedles having a surface including a nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated; and administering via the plurality of microneedles a therapeutically effective amount of an anti-CTLA-4 antibody effective to prevent or reduce metastasis of the cancer into lymphatic capillaries and / or lymphatic vessels draining the intervening lymph nodes. The method includes:
[0050] Embodiment 40 is a method of treating cancer in a patient, comprising: placing a medical device including a plurality of microneedles on the patient's skin proximate to a first location beneath the patient's skin, the first location proximate to a lymphatic vessel and / or lymphatic capillary of the patient's lymphatic system, the microneedles having a surface including a nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to a first location; and administering an anti-CTLA-4 antibody to the first location via the plurality of microneedles, thereby treating the cancer. The method includes:
[0051] Embodiment 41 is a method according to any one of embodiments 38 to 40, wherein the cancer comprises a tumor.
[0052] Embodiment 42 is a method according to any one of embodiments 38 to 41, wherein the medical device is placed distal to the inflow trunk relative to the tumor.
[0053] Embodiment 43 is a method according to embodiments 38-42, wherein at least one lymph node of the patient is interposed in the lymphatic system between the tumor and the draining lymphatic system, and the first location is located between the interposed lymph node and the tumor.
[0054] Embodiment 44 is a method according to any one of embodiments 38-43, wherein the medical device is placed at a location on the patient's skin that has lymphatic capillaries and / or lymphatic vessels that drain directly to an intervening lymph node without first passing through any preceding lymph nodes.
[0055] In embodiment 45, the cancer is a head and neck cancer and the lymph nodes are jugular lymph nodes. lymph nodes, cervical lymph nodes, supraclavicular lymph nodes, and combinations thereof The method according to any one of embodiments 38 to 44, selected.
[0056] Embodiment 46 is a method according to any one of embodiments 38-44, wherein the cancer is oral cancer and the lymph nodes are selected from the group consisting of the jugular lymph node chain, cervical lymph nodes, supraclavicular lymph nodes, and combinations thereof.
[0057] Embodiment 47 is a method according to any one of embodiments 38 to 44, wherein the cancer is a pharyngeal cancer and the lymph nodes are selected from the group consisting of the jugular lymph node chain, the cervical lymph nodes, the supraclavicular lymph nodes, and combinations thereof.
[0058] Embodiment 48 is a method according to any one of embodiments 38 to 44, wherein the cancer is melanoma and the lymph nodes are selected from the group consisting of axillary lymph nodes, inguinal lymph nodes, jugular lymph nodes, cervical lymph nodes, supraclavicular lymph nodes, and combinations thereof.
[0059] Embodiment 49 is a method according to any one of embodiments 38-44, wherein the cancer is breast cancer and the lymph nodes are selected from the group consisting of axillary lymph nodes, internal mammary lymph nodes, supraclavicular lymph nodes, and combinations thereof.
[0060] Embodiment 50 is the method according to any one of embodiments 38-44, wherein the cancer is prostate cancer and the lymph nodes are selected from the group consisting of lumbar lymph nodes, inguinal lymph nodes, peritoneal lymph nodes, and combinations thereof.
[0061] Embodiment 51 is a method according to any one of embodiments 38 to 44, wherein the cancer is in the patient's reproductive system, with the proviso that the cancer is not ovarian cancer, and the lymph nodes are selected from the group consisting of lumbar lymph nodes, inguinal lymph nodes, peritoneal lymph nodes, and combinations thereof.
[0062] Embodiment 52 is a method according to any one of embodiments 38 to 51, wherein the anti-CTLA-4 antibody is imilimumab, a biosimilar thereof or a biological equivalent thereof.
[0063] Embodiment 53 is a method for treating an inflammatory medical condition in a patient, comprising: locating at least one inflammatory locus in the patient, the at least one inflammatory locus comprising a lymphatic vessel, a lymphatic capillary, a lymph node, a lymphatic organ, or any combination thereof; Locating a first location in the patient's lymphatic system upstream of a site of inflammation; placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location, the microneedles having a surface including a nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated; and administering, via the plurality of microneedles, to the first location, a therapeutically effective amount of an immunosuppressant effective to treat the inflammatory medical condition. The method includes:
[0064] Embodiment 54 is a method according to embodiment 53, wherein the upstream location of the lymphatic system is a lymph node selected from the group consisting of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof.
[0065] Embodiment 55 is a method according to any one of embodiments 53 or 54, wherein at least one site of inflammation in the patient is a joint or a psoriatic lesion.
[0066] Embodiment 56 is a method according to any one of embodiments 53 to 55, wherein the at least one site of inflammation in the patient is at least one joint selected from the group consisting of ankle joints, knee joints, hip joints, shoulder joints, elbow joints, metacarpophalangeal joints of the hand, metatarsophalangeal joints of the foot, wrist joints, neck joints, and combinations thereof.
[0067] Embodiment 57 is a method according to any one of embodiments 53 to 56, wherein at least one site of inflammation in the patient is a psoriatic lesion.
[0068] Embodiment 58 is a method according to any one of embodiments 53-57, wherein the inflammatory medical condition is selected from the group consisting of Behcet's disease, sarcoidosis, rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, non-infectious uveitis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and combinations thereof.
[0069] Embodiment 59 is a method for reducing TNF-α levels in a patient, comprising: Locating a first location in the patient's lymphatic system; placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location, the microneedles having a surface including a nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated; and administering, via the plurality of microneedles, to the first location, a therapeutically effective amount of an immunosuppressant effective to reduce TNF-α levels in the patient. The method includes:
[0070] Embodiment 60 is a method according to embodiment 59, wherein the first location is at least one lymph node of the patient.
[0071] Embodiment 61 is a method for treating an inflammatory medical condition in a patient, comprising: Locating at least one site of inflammation in the patient, including a lymph node, a lymphatic capillary, a lymphatic vessel, a lymphatic organ, or any combination thereof; placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location beneath the patient's skin, the first location being positioned to include selected lymphatic capillaries and / or lymphatic vessels that deliver lymph directly to the lymphatic system at the site of inflammation, the microneedles having a surface including a nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated; and administering, via the plurality of microneedles, to selected lymphatic capillaries and / or lymphatic vessels of the patient, a therapeutically effective amount of an immunosuppressant effective to treat the inflammatory medical condition. The method includes:
[0072] Embodiment 62 is a method for treating an inflammatory medical condition in a patient, comprising: placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location beneath the patient's skin, the first location being positioned to include lymphatic capillaries and / or lymphatic vessels that deliver lymph directly to the lymphatic system, the microneedles having a surface including a nanotopography; inserting a plurality of microneedles into a patient to a depth whereby at least the epithelium is penetrated; and administering an immunosuppressant to the patient's lymphatic capillaries and / or lymphatic vessels via the plurality of microneedles, thereby treating the inflammatory medical condition. The method includes:
[0073] Embodiment 63 is a method according to any one of embodiments 53 to 62, wherein the first location is located to include selected lymphatic capillaries and / or lymphatic vessels that deliver lymph directly to the patient's lymphatic system at the site of inflammation, including a lymph node, lymphatic capillaries, lymphatic vessels, lymphatic organs, or any combination thereof.
[0074] Embodiment 64 is a method according to any one of embodiments 53 to 63, wherein the selected lymphatic capillaries and / or lymphatic vessels are located distal to the patient's heart, relative to the site of inflammation.
[0075] Embodiment 65 is a method according to any one of embodiments 53 to 64, wherein at least one site of inflammation in the patient is a joint.
[0076] Embodiment 66 is a method according to any one of embodiments 53 to 65, wherein the at least one site of inflammation in the patient is at least one joint selected from the group consisting of ankle joints, knee joints, hip joints, shoulder joints, elbow joints, metacarpophalangeal joints of the hand, metatarsophalangeal joints of the foot, wrist joints, neck joints, and combinations thereof.
[0077] Embodiment 67 is a method according to any one of embodiments 53-66, wherein the site of inflammation is the knee and the selected lymphatic capillaries and / or lymphatic vessels drain into the popliteal lymph node.
[0078] Embodiment 68 is a method according to any one of embodiments 53-66, wherein the site of inflammation is a knee, and for the knee, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0079] Embodiment 69 is a method according to any one of embodiments 53 to 66, wherein the site of inflammation is the neck and the selected lymphatic capillaries and / or lymphatic vessels drain to cervical lymph nodes.
[0080] Embodiment 70 is a method according to any one of embodiments 53-66, wherein the site of inflammation is the neck, and for the neck, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0081] Embodiment 71 is a method according to any one of embodiments 53 to 66, wherein the site of inflammation is a shoulder and the selected lymphatic capillaries and / or lymphatic vessels drain to thoracic lymph nodes, supraclavicular lymph nodes, axillary lymph nodes, or any combination thereof.
[0082] Embodiment 72 is a method according to any one of embodiments 53-66, wherein the site of inflammation is a shoulder, and for the shoulder, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0083] Embodiment 73 is a method according to any one of embodiments 53 to 66, wherein the site of inflammation is an elbow and the selected lymphatic capillaries and / or lymphatic vessels drain to the medial epicondyle lymph nodes and / or brachial lymph nodes.
[0084] Embodiment 74 is a method according to any one of embodiments 53-66, wherein the site of inflammation is an elbow, and relative to the elbow, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0085] Embodiment 75 is a method according to any one of embodiments 53-66, wherein the site of inflammation is the hip joint and the selected lymphatic capillaries and / or lymphatic vessels drain to inguinal lymph nodes and / or pelvic lymph nodes.
[0086] Embodiment 76 is a method according to any one of embodiments 53-66, wherein the site of inflammation is a hip joint, and relative to the hip joint, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0087] Embodiment 77 is a method according to any one of embodiments 53-66, wherein the site of inflammation is a hip joint, and for the hip joint, the selected lymphatic capillaries and / or lymphatic vessels are located proximate to the heart.
[0088] Embodiment 78 is a method according to any one of embodiments 53 to 77, wherein the inflammatory medical condition is rheumatoid arthritis.
[0089] Embodiment 79 is a method according to any one of embodiments 53 to 78, wherein the inflammatory site is a psoriatic lesion.
[0090] Embodiment 80 is a method according to embodiment 79, wherein the selected lymphatic capillaries share common lymphatic vessels and / or lymphatic capillaries directly adjacent to and / or within the psoriatic lesion.
[0091] Embodiment 81 is a method according to embodiment 79 or 80, wherein the medical device is placed at a location on the patient's skin that has lymphatic capillaries and / or lymphatic vessels that are within a psoriatic lesion and / or drain directly to the lymph nodes closest to the psoriatic lesion.
[0092] Embodiment 82 is a method for administering a first therapeutic agent to selected lymphatic capillaries and / or lymphatic vessels distal to the heart to a site of inflammation;
[0093] The method according to embodiment 81, wherein the method further comprises administering a second therapeutic agent, which is an immunosuppressant, to selected lymphatic capillaries and / or lymphatic vessels proximate to the heart via the second medical device.
[0094] Embodiment 83 is a method according to embodiment 82, wherein the second therapeutic agent is the same or different from the antibody that inhibits TNF-α or etanercept, or a biosimilar or biological equivalent thereof, administered to the first location.
[0095] Embodiment 84 is a method according to any one of embodiments 53 to 83, wherein the immunosuppressant is a TNF-α inhibitor.
[0096] Embodiment 85 is the method according to any one of embodiments 53 to 83, wherein the immunosuppressant is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, ustekinumab, rituximab, secukinumab, omalizumab, natalizumab, ixekizumab, obinutuzumab, rituximab / hyaluronidase human, or a biosimilar or bioequivalent of any of the foregoing.
[0097] Embodiment 86 is a method according to any one of embodiments 53 to 83, wherein the immunosuppressant is an antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof.
[0098] Embodiment 87 is a method according to any one of embodiments 53 to 83, wherein the immunosuppressant is adalimumab or a biosimilar or biological equivalent thereof.
[0099] Embodiment 88 is a method according to any one of embodiments 53 to 83, wherein the immunosuppressant is etanercept or a biosimilar or bioequivalent thereof.
[0100] Embodiment 89 is the method according to embodiment 86, wherein the antibody that inhibits TNF-α or etanercept, or a biosimilar or biological equivalent thereof, is adalimumab, or a biosimilar or biological equivalent thereof.
[0101] Embodiment 90 is the method according to embodiment 86, wherein the antibody that inhibits TNF-α or etanercept, or a biosimilar or biological equivalent thereof, is etanercept, or a biosimilar or biological equivalent thereof.
[0102] Embodiment 91 is a method according to any one of embodiments 53 to 90, wherein the first medical device is positioned at a location on the patient's skin that is within the site of inflammation and / or has lymphatic capillaries and / or lymphatic vessels that drain directly to the lymph node closest to the site of inflammation.
[0103] Embodiment 92 is a method according to any one of embodiments 53 to 91, wherein the selected lymphatic capillaries and / or lymphatic vessels are distal to the heart relative to the site of inflammation.
[0104] Embodiment 93 is a method according to any one of embodiments 53 to 92, wherein the selected lymphatic capillaries and / or lymphatic vessels are in cardiac proximity to the site of inflammation.
[0105] Embodiment 94 is a method according to any one of embodiments 1 to 93, wherein the patient is a mammal.
[0106] Embodiment 95 is a method according to any one of embodiments 1 to 94, wherein the patient is a human.
[0107] Embodiment 96 is a method according to any one of embodiments 1 to 95, wherein the medical device is a Sofusa™ drug delivery platform.
[0108] Embodiment 97 is a medical device comprising a fluid delivery device, 12. A fluid delivery device comprising: a fluid dispensing assembly, the cap assembly coupled to the cartridge assembly, the cartridge assembly slidably coupled to the plenum assembly, and the mechanical controller assembly slidably coupled to the cartridge assembly; a collet assembly forming a housing for the fluid delivery device and slidably coupled to the fluid dispensing assembly; and a plurality of microneedles in fluid communication with a fluid distribution assembly, the plurality of microneedles having a surface including nanotopography, the plurality of microneedles being capable of penetrating the stratum corneum of a patient's skin and controllably delivering a therapeutic agent, an anti-CTLA-4 antibody, or an immunosuppressant to a depth below the surface of the skin; The method according to any one of embodiments 1 to 96, comprising:
[0109] Embodiment 98 is a method according to any one of embodiments 1 to 97, wherein the medical device delivers the therapeutic agent or anti-CTLA-4 antibody or immunosuppressant to a depth of about 50 μm to about 4000 μm, about 250 μm to about 2000 μm, or about 350 μm to about 1000 μm below the surface of the skin.
[0110] Embodiment 99 is a method according to any one of embodiments 1 to 98, wherein each of the microneedles of the medical device has a length of about 200 to about 800 μm, about 250 to about 750 μm, or about 300 to about 600 μm. [Brief description of the drawings]
[0111] [Figure 1] FIG. 1 shows the locations of important lymph nodes in the rat.
[0112] [Diagram 2] FIG. 2 is a graph of the PK profile of etanercept in rat serum.
[0113] [Figure 3-1]3A, 3B, 3C, and 3D are graphs showing the biodistribution of etanercept in a rat model. FIG. 3A is a graph showing the biodistribution of etanercept administered either intravenously ("IV") or via the Sofusa™ drug delivery platform after 12 hours. FIG. 3B is a graph showing the biodistribution of etanercept administered either subcutaneously ("SC") or via the Sofusa™ drug delivery platform after 12 hours. FIG. 3C is a graph showing the biodistribution of etanercept administered either via IV or via the Sofusa™ drug delivery platform after 36 hours. FIG. 3D is a graph showing the biodistribution of etanercept administered either via SC or via the Sofusa™ drug delivery platform after 36 hours. [Figure 3-2] 3A, 3B, 3C, and 3D are graphs showing the biodistribution of etanercept in a rat model. FIG. 3A is a graph showing the biodistribution of etanercept administered either intravenously ("IV") or via the Sofusa™ drug delivery platform after 12 hours. FIG. 3B is a graph showing the biodistribution of etanercept administered either subcutaneously ("SC") or via the Sofusa™ drug delivery platform after 12 hours. FIG. 3C is a graph showing the biodistribution of etanercept administered either via IV or via the Sofusa™ drug delivery platform after 36 hours. FIG. 3D is a graph showing the biodistribution of etanercept administered either via SC or via the Sofusa™ drug delivery platform after 36 hours.
[0114] [Figure 4] FIG. 4 is a graph summarizing the biodistribution of etanercept in the axillary and inguinal lymph nodes when administered intravenously, subcutaneously, intradermally ("ID"), or via the Sofusa™ drug delivery platform.
[0115] [Figure 5-1]FIG. 5A shows a timeline of induction, measurements and treatment of animals with collagen-induced arthritis.
[0116] [Figure 5-2] Figures 5B-5G are graphs showing lymphatic pumping rate (y-axis) versus % joint swelling (x-axis) in a CIA RA rat model comparing administration of etanercept via the Sofusa™ drug delivery platform versus subcutaneous administration measured on days 11 (Figures 5B and 5C), 13 (Figures 5D and 5E), and 18 (Figures 5F and 5G), respectively, after CIA injection. [Figure 5-3] Figures 5B-5G are graphs showing lymphatic pumping rate (y-axis) versus % joint swelling (x-axis) in a CIA RA rat model comparing administration of etanercept via the Sofusa™ drug delivery platform versus subcutaneous administration measured on days 11 (Figures 5B and 5C), 13 (Figures 5D and 5E), and 18 (Figures 5F and 5G), respectively, after CIA injection. [Figure 5-4] Figures 5B-5G are graphs showing lymphatic pumping rate (y-axis) versus % joint swelling (x-axis) in a CIA RA rat model comparing administration of etanercept via the Sofusa™ drug delivery platform versus subcutaneous administration measured on days 11 (Figures 5B and 5C), 13 (Figures 5D and 5E), and 18 (Figures 5F and 5G), respectively, after CIA injection.
[0117] [Figure 6] FIG. 6 is a graph of lymphatic pumping rate following administration of etanercept either subcutaneously or via the Sofusa™ drug delivery platform.
[0118] [Figure 7-1] 7A, 7B, 7C, and 7D are a series of graphs showing lymphatic pumping rate following administration of etanercept when administered via the Sofusa™ drug delivery platform (FIG. 7A), subcutaneous injection (FIG. 7B), untreated control (FIG. 7C), and intradermal injection (FIG. 7D). [Figure 7-2] 7A, 7B, 7C, and 7D are a series of graphs showing lymphatic pumping rate following administration of etanercept when administered via the Sofusa™ drug delivery platform (FIG. 7A), subcutaneous injection (FIG. 7B), untreated control (FIG. 7C), and intradermal injection (FIG. 7D).
[0119] [Figure 8] FIG. 8 shows a comparison of the PK curves of etanercept when administered either via the Sofusa™ drug delivery platform or subcutaneous injection.
[0120] [Figure 9] FIG. 9 is a graph of the PK profile of etanercept over 48 hours for intravenous and subcutaneous administration compared to the Sofusa™ drug delivery platform.
[0121] [Figure 10] FIG. 10 is a graph comparing the PK / PD profiles of intravenous, subcutaneous and intradermal etanercept compared to the Sofusa™ drug delivery platform.
[0122] [Figure 11] FIG. 11 is a series of bioluminescence images showing the metastatic burden of mice treated with either vehicle or anti-mCTLA-4 monotherapy administered using the Sofusa™ drug delivery platform.
[0123] [Figure 12] FIG. 12 is a graph comparing tumor volumes in rats treated with anti-mCTLA-4 monotherapy administered IP or via the Sofusa™ drug delivery platform.
[0124] [Figure 13] FIG. 13 is a cross-sectional view of an exemplary fluid delivery device in a pre-use configuration.
[0125] [Figure 14] FIG. 14 is a cross-sectional view of a fluid delivery device in a pre-actuated configuration.
[0126] [Figure 15] FIG. 15 is an exploded cross-sectional view of a fluid delivery device.
[0127] [Figure 16] FIG. 16 is a cross-sectional view of a collet assembly of a fluid delivery device.
[0128] [Figure 17] 17 is an exploded perspective view of the collet assembly shown in FIG. 16. FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0129] Unless otherwise indicated, the drawings provided herein depict the results of representative experiments illustrating features of embodiments of the present disclosure or some aspects of the subject matter disclosed herein. It is believed that these features and / or results are applicable to a wide variety of systems, including one or more embodiments of the present disclosure. Thus, the drawings are not intended to include all additional features known to those skilled in the art that are required to practice the embodiments, nor are they intended to limit the potential uses of the methods disclosed herein.
[0130] Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying drawings. Although the invention will be described in conjunction with the illustrated embodiments, it will be understood that they are not intended to limit the invention to these embodiments. On the contrary, the invention is intended to encompass all alternatives, modifications, and equivalents that may be included within the invention as defined by the appended claims. The section headings used herein are for organizational purposes only and should not be construed in any manner as limiting the desired subject matter. In the event that any document incorporated by reference conflicts with any term defined herein, the present specification shall control.
[0131] In the following specification and claims, reference will be made to a number of terms that shall be defined to have the following meanings: The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. The terms "comprising," "including," and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements. "Optionally" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances when the event does or does not occur.
[0132] As used herein throughout the specification and claims, approximation terms may be applied to modify any quantitative expression that may be permissibly varied without causing a change in the basic function involved. Thus, values modified by one or more terms such as "about", "approximately" and "substantially" are not limited to the exact value specified. In at least some cases, approximation terms may correspond to the precision of the instrument for measuring the value. Here, and throughout the specification and claims, range limitations may be combined and / or interchangeable. Such ranges are specified and include all subranges contained therein unless otherwise indicated by context or language. Numeric ranges include the numbers that define the range.
[0133] As used herein, terms relating to position such as upward, downward, upper, lower, top, bottom, etc. are used merely as a matter of convenience to indicate relative positional relationships. I. Definition
[0134] The terms "medicine", "pharmaceutical therapy", "medicine", "therapeutic agent" and "drug" are used interchangeably herein to describe a pharmaceutical composition or product intended for the treatment of a medical condition having at least one symptom. The pharmaceutical composition or product exerts a physiological effect on the patient when introduced into the patient's body. The pharmaceutical composition may be in any suitable formulation, unless a specific type of formulation is required or disclosed. In some cases, the medicament is approved by the US FDA, while in other cases, the medicament may be in an experimental stage (e.g., clinical trials) or approved for use in countries other than the United States (e.g., approved for use in China or Europe). When these terms are used, it is understood that the terms refer to both the singular and the plural. In some embodiments herein, two or more medicaments may be used in the form of a combination therapy. In either case, the selection of the appropriate medicament(s) is based on the evaluation of the patient's medical condition and the medical professional administering, monitoring and / or directing the patient's treatment. Combination therapy is sometimes more effective than a single agent and is used for many different medical conditions. It is understood that combination therapy is encompassed herein and contemplated in conjunction with the disclosed subject matter.
[0135] An "effective amount" or "therapeutically effective dose" in relation to a pharmaceutical is an amount sufficient to treat, ameliorate, or reduce the intensity of at least one symptom associated with a medical condition. In some aspects of the present disclosure, an effective amount of a pharmaceutical is an amount sufficient to produce a beneficial or desired clinical result, including relief or reduction of one or more symptoms of a medical condition. In some embodiments, an effective amount of a pharmaceutical is an amount sufficient to alleviate all symptoms of a medical condition. In some aspects, a dose of a therapeutic agent is administered that is not therapeutically effective by itself. In these aspects, multiple doses may be administered to a patient sequentially (using the same device or different devices) or simultaneously, such that the combination of the individual doses is therapeutically effective. For simultaneous administration, an additional medical device containing multiple microneedles or an entirely different route of administration may be used.
[0136] As used herein, the term "patient" refers to a warm-blooded animal, such as a mammal, that is the subject of medical treatment for a medical condition that causes at least one symptom. It is understood that at least humans, dogs, cats and horses are within the meaning of this term. Preferably, the patient is a human.
[0137] As used herein, the terms "distal" and "proximal" are used in their anatomical sense. Distal means that a given location or structure is located further away from the center of the body or the junction of a limb than another location or structure. Proximal is the opposite of distal. Proximal means that a given location or structure is located closer to the center of the body or the junction of a limb than another location or structure. For example, the wrist is distal to the elbow and the shoulder is proximal to the elbow.
[0138] As used herein, the term "treat" or "treatment" or derivatives thereof contemplate partial or complete improvement of at least one symptom associated with a patient's medical condition. "Preventing" a medical condition from occurring (e.g., metastasis of cancer) is considered a form of treatment. "Reducing" the occurrence of a medical condition (e.g., metastasis of cancer) is considered a form of treatment.
[0139] Etanercept is a fusion protein produced by recombinant DNA sold under the trade name Enbrel®. Etanercept fuses the TNF receptor to the constant end of an IgGI antibody, and when administered to patients, it reduces the action of naturally occurring TNF. It is therefore considered a TNF inhibitor. In the United States, etanercept has been approved by the FDA for clinical use in the treatment of moderate to severe rheumatoid arthritis (RA), moderate to severe polyarticular juvenile rheumatoid arthritis (JRA), psoriatic arthritis, ankylosing spondylitis, and moderate to severe plaque psoriasis. Due to the significant number of secondary infections associated with Enbrel®, the FDA has requested a black box warning, which is the most serious level of warning possible under current FDA guidelines. As used herein, the terms etanercept and Enbrel® are used interchangeably and also include any biosimilars or bioequivalents thereof.
[0140] Checkpoint inhibitors are a form of cancer treatment that directly affects the function of the patient's immune system. Immune system checkpoints can be either stimulatory or inhibitory, and some cancers are known to affect these checkpoints to prevent the immune system from attacking them. Thus, checkpoint inhibitors can block these inhibitory checkpoints, thereby restoring proper immune system function. Examples of checkpoints include, but are not limited to, CTLA-4, PD-1, and PD-L1. Some checkpoint inhibitors currently approved by the FDA include, but are not limited to, ipilimumab (CTLA-4 inhibitor, sold under the trade name Yervoy®), nivolumab (PD-1 inhibitor, sold under the trade name Opdivo®), pembrolizumab (PD-1 inhibitor, sold under the trade name Keytruda®), and atezolizumab (PD-L1 inhibitor, sold under the trade name Tecentriq®). As used herein, the term checkpoint inhibitors encompasses pharmaceutical agents used to inhibit immune system checkpoints and restore immune system function.
[0141] As used herein, "bioavailability" refers to the total amount of an administered drug of a given dosage that reaches the blood compartment, which is commonly measured as the area under the curve (AUC) in a plot of concentration versus time.
[0142] As used herein, the phrase "side effects" includes the undesirable and harmful effects of a preventive or therapeutic agent. Although harmful effects are always undesirable, undesirable effects are not necessarily harmful. The harmful effects of a preventive or therapeutic agent may be harmful, uncomfortable, or dangerous. Side effects of chemotherapy include, but are not limited to, gastrointestinal toxicity, including, but not limited to, early and late diarrhea and flatulence, nausea, vomiting, anorexia, leukopenia, anemia, neutropenia, asthenia, abdominal cramps, fever, pain, weight loss, dehydration, alopecia, dyspnea, insomnia, dizziness, mucositis, xerostomia, and renal failure, as well as constipation, nerve and muscle effects, temporary or permanent damage to the kidneys and bladder, flu-like symptoms, fluid retention, and temporary or permanent infertility. Side effects of radiation therapy include, but are not limited to, fatigue, dry mouth, and anorexia. Side effects of biological therapy / immunotherapy include but are not limited to rash or swelling at the administration site, flu-like symptoms such as fever, chills and fatigue, gastrointestinal problems and allergic reactions.Side effects of hormone therapy include but are not limited to nausea, fertility problems, depression, loss of appetite, eye problems, headache and weight fluctuation.There are many other unwanted effects that patients typically experience and are known in the art.See, for example, the Physicians' Desk Reference (69th ed., 2015), which is incorporated herein by reference in its entirety.
[0143] C max refers to the maximum concentration that a drug achieves in the plasma or tissues of a patient after it is administered, while C trefers to the concentration that a drug achieves at a particular time (t) after administration. Unless otherwise stated, all discussions herein relate to pharmacokinetic parameters in plasma.
[0144] AUC t refers to the area under the plasma concentration time curve from time zero to time t after administration of a drug.
[0145] AUC ∞ refers to the area under the plasma concentration time curve from time zero to infinity (infinity means that the plasma concentration of the drug is below detectable levels).
[0146] T max T is the time required for the concentration of a drug to reach its maximum plasma concentration in a patient after administration. Some forms of drug administration slowly max (e.g., tablets and capsules taken orally), but other forms of administration reach the T almost immediately. max (e.g., subcutaneous and intravenous administration).
[0147] "Steady state" refers to a situation in which the total intake of a drug is in approximately dynamic equilibrium with its excretion.
[0148] A discussion of various pharmacokinetic parameters and how to measure and calculate them can be found in Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, M. Rowland and TN Tozer, (Lippincott, Williams & Wilkins, 2010), the teachings of which are incorporated by reference.
[0149] "Or" is used in its inclusive sense, ie, equivalent to "and / or," unless the context requires otherwise. II. Lymphatic Delivery Methods
[0150] In the methods disclosed herein, two different exemplary modes for delivering a therapeutic agent to a patient are envisioned. In one mode, the target of the therapeutic agent is clearly identified, and a medical device including a plurality of microneedles is positioned to be administered to the patient's lymphatic system, such that the pharmaceutical agent is transported directly to the target by lymphatic vessels. The target may be, for example, a solid tumor or a particularly inflamed joint of the patient. In this case, although some systemic exposure occurs, administration is much more localized. In a second mode, the therapeutic target or exact location of the target may be unknown or less clearly defined, and the therapeutic agent is delivered to the patient's lymphatic system, with the agent intended to pass through the lymphatic system until it reaches either the right lymphatic trunk or the thoracic duct. The therapeutic agent then enters the patient's circulatory system, resulting in systemic exposure of the agent. For example, if a solid tumor has metastasized, the location of these secondary sites of cancer cells may be unknown. Also, for some inflammatory medical conditions (e.g., Crohn's disease), the exact target of delivery of the therapeutic agent is unknown. Although the therapeutic agent may pass through certain lymph nodes before reaching any of the draining trunks, administration is considered to result in systemic exposure. Thus, one skilled in the art can apply the disclosed methods to provide targeted local administration or more widespread systemic administration of the therapeutic agent. A medical professional can determine which mode of administration is appropriate for an individual patient and position one or more medical devices accordingly.
[0151] In some aspects, the therapeutic target is a lymph node, a lymphatic vessel, an organ that is part of the lymphatic system, or a combination thereof. In some aspects, the therapeutic target is a lymph node. In some aspects, the therapeutic target is a specific lymph node as described elsewhere herein.
[0152] In some embodiments, the delivery of the therapeutic agent to the lymphatic system is to a vessel of the lymphatic system, a lymph node, or both, as described elsewhere herein. In some aspects, the delivery is to a superficial lymphatic vessel. In yet other aspects, the delivery is to one or more lymph nodes. The particular target of delivery is based on the medical needs of the patient.
[0153] In patients where more than one medical device is used to deliver therapeutic agent to multiple locations in the patient's body, the total dosage of therapeutic agent at each location must be carefully adjusted so that the patient does not receive a combined dosage of drugs that is generally unsafe.More selective targeting of specific locations in or on the patient's body means that a lower dosage is often required at each specific location.In some embodiments, the dosage administered to target one or more locations in the patient's body is lower than the dosage administered by other routes, including intravenous and subcutaneous administration.
[0154] Lymph circulates throughout a patient's body in a manner similar to blood in the circulatory system, so any single location in the lymphatic system may be upstream or downstream relative to another location. As used herein with respect to the lymphatic system, the term "downstream" refers to a location in the lymphatic system that is closer to either the right lymphatic trunk or the thoracic duct (as the fluid passes through the ducts in a healthy patient) relative to a reference location (e.g., a tumor or viscera or a joint). As used herein, the term "upstream" refers to a location in the lymphatic system that is farther away from the right lymphatic trunk or the thoracic duct relative to a reference location. The terms "upstream" and "downstream" do not specifically refer to the direction of fluid flow in a patient undergoing a medical procedure, because the direction of fluid flow in the lymphatic system may be poor or reversed depending on the patient's medical condition. The terms are location-related terms based on their physical location relative to the inflow trunk described.
[0155] Lymph nodes often occur in groups, rather than existing as single, isolated nodes, so the term "lymph node" as used herein may be singular or plural, and refers to either a single, isolated lymph node or a group of lymph nodes in a small physical location.For example, a reference to one or more inguinal lymph nodes refers to a group of lymph nodes recognized by those skilled in the art (i.e., a medical professional such as a doctor or nurse) as a group of lymph nodes located in the hip / groin area or femoral triangle of a patient.The term also refers to both superficial and deep lymph nodes, unless otherwise specified.In some embodiments, the lymph node is the sentinel lymph node of a particular solid cancer tumor.
[0156] In some embodiments, the lymph nodes are selected from the group consisting of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, extra-aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof.
[0157] In some embodiments, two or more different lymph nodes are selected. In some embodiments, three or more different lymph nodes are selected. The lymph nodes may be on either side of the patient's body. In yet another embodiment, the lymph nodes are inguinal lymph nodes. The inguinal lymph nodes may be right inguinal lymph nodes, left inguinal lymph nodes, or both. In yet another embodiment, the lymph nodes are axillary lymph nodes. The axillary lymph nodes may be right axillary lymph nodes, left axillary lymph nodes, or both.
[0158] In some embodiments, two or more different lymph nodes are selected. In some embodiments, three or more different lymph nodes are selected. The lymph nodes may be on either side of the patient's body. In yet another embodiment, the lymph nodes are inguinal lymph nodes. The inguinal lymph nodes may be right inguinal lymph nodes, left inguinal lymph nodes, or both. In yet another embodiment, the lymph nodes are axillary lymph nodes. The axillary lymph nodes may be right axillary lymph nodes, left axillary lymph nodes, or both.
[0159] In some embodiments, the medicament is delivered to the patient's interstitium, for example, the space between the skin and one or more body structures such as an organ, muscle or vessel (artery, vein or lymphatic vessel), or any other space within or between tissues or portions of an organ. In yet other embodiments, the medicament is delivered to both the interstitium and the lymphatic system. In embodiments in which a therapeutic agent is delivered to the patient's interstitium, it may not be necessary to locate the patient's lymph nodes or lymphatic system prior to administration of the therapeutic agent. III. Administration of Therapeutic Agents to Multiple Regions of the Lymphatic System
[0160] One embodiment disclosed herein is a method for administering a therapeutic agent to a patient's lymphatic system. The method generally includes the steps of: placing a first medical device including a plurality of microneedles on the patient's skin at a first location proximate to a first location under the patient's skin, the first location being proximate to lymphatic vessels and / or lymphatic capillaries draining into the right lymphatic trunk, the microneedles of the first medical device having a surface that includes nanotopography; placing a second medical device including a plurality of microneedles on the patient's skin at a second location proximate to a second location under the patient's skin, the second location being proximate to lymphatic vessels and / or lymphatic capillaries draining into the thoracic duct, the microneedles of the second medical device having a surface that includes nanotopography; the microneedles of the first medical device into the patient to a depth whereby at least the epithelium is penetrated and at least one end of the microneedles is proximate to a first location; inserting a plurality of microneedles of a second medical device into the patient to a depth whereby at least the epithelium is penetrated and at least one end of the microneedles is proximate to a second location; and administering a first dose of a therapeutic agent via the microneedles of the first medical device to the first location and administering a second dose of a therapeutic agent via the microneedles of the second medical device to the second location, wherein administration of both doses cumulatively provides a therapeutically effective amount of the therapeutic agent.
[0161] In some aspects, a method for administering a therapeutic agent to a patient's lymphatic system is disclosed herein. The method generally includes the steps of: placing a first medical device including a plurality of microneedles on the patient's skin at a first location proximate to a first location under the patient's skin, the first location being proximate to lymphatic vessels and / or lymphatic capillaries draining into the right lymphatic trunk, and the microneedles of the first medical device having a surface that includes nanotopography; placing a second medical device including a plurality of microneedles on the patient's skin at a second location proximate to a second location under the patient's skin, the second location being proximate to lymphatic vessels and / or lymphatic capillaries draining into the thoracic duct, and the microneedles of the second medical device having a surface that includes nanotopography; the step of inserting a plurality of microneedles of a second medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate to a first location; inserting a plurality of microneedles of a second medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate to a second location; administering a first therapeutically effective dose of a therapeutic agent to the first location via the microneedles of the first medical device; and administering a second therapeutically effective dose of a therapeutic agent to the second location via the microneedles of the second medical device, wherein the administration start times of the first dose and the second dose are different and separated by a period of time.
[0162] In some embodiments disclosed herein, the first and second locations are reversed, with the first location proximate to lymphatic vessels and / or lymph capillaries draining into the thoracic duct and the second location proximate to lymphatic vessels and / or lymph capillaries draining into the right lymphatic trunk. As described, one medical device drains into one of two draining trunks of the lymphatic system, while the other medical device drains into the other draining trunk. The method contemplates administering at least a therapeutic agent to the patient's lymphatic system such that different portions of the lymphatic system are exposed to the therapeutic agent. In some embodiments, two or more medical devices are positioned to drain into the same draining trunk but target different regions of the patient's lymphatic system. For example, one device may be positioned in the patient's left arm and one device may be positioned in the patient's left leg. Although the therapeutic agent ultimately drains through the same trunk as the administration site, the therapeutic agent passes through significantly different regions of the patient's lymphatic system.
[0163] In some embodiments, the first dose of therapeutic agent and the second dose of therapeutic agent are not individually therapeutically effective, but the combined dose amount is therapeutically effective. The first dose and the second dose can be administered sequentially or simultaneously. In some embodiments, the first dose and the second dose are administered sequentially. In some embodiments, the first dose and the second dose are administered simultaneously. In some embodiments, the administration of the two doses overlaps at least partially in time. This means that the administration of the two doses starts at different times, but the administration of the second dose starts before the administration of the first dose ends.
[0164] The location on the patient's body is selected based on the patient's medical condition and the knowledge of the medical professional who will be monitoring, prescribing and / or administering the treatment. For each medical device used with the methods disclosed herein, the location of the medical device on the patient's body is selected independently of the other medical devices, with the caveat that the purpose of the method is to expose different parts of the lymphatic system to the therapeutic agent. In some embodiments, each medical device is placed on the patient's limb (i.e., arm or leg). To achieve maximum exposure of the lymphatic system to the therapeutic agent, one device is placed on the patient's right arm while the other device is placed on the patient's left leg. Alternatively, one device may be placed on the patient's left arm while the other device is placed on the patient's right leg. In yet another embodiment, one medical device is placed on the patient's right arm while the other medical device is placed on either the patient's left arm or left leg. In yet another embodiment, one medical device is placed on the patient's left arm and the other medical device is placed on the patient's right arm or right leg. The device on the patient's arm may be positioned adjacent to the patient's wrist or hand, while the device on the patient may be positioned adjacent to the patient's ankle or foot.
[0165] In yet another aspect, the method disclosed herein further includes placing a third medical device comprising a plurality of microneedles on the patient's skin at a third location beneath the patient's skin proximate a third location, the third location proximate a lymphatic vessel and / or lymphatic capillaries; inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate the third location; and administering a third dose of said therapeutic agent via the third medical device, the third location being distinct from the first location and the second location, and the third location being distinct from the first location and the second location.
[0166] In yet another aspect, the method disclosed herein further comprises the steps of placing a fourth medical device comprising a plurality of microneedles on the patient's skin at a fourth location proximate a fourth location under the patient's skin, the fourth location being proximate a lymphatic vessel and / or lymphatic capillary; inserting the plurality of microneedles of the fourth medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate the fourth location; and administering a fourth dose of the therapeutic agent via the fourth medical device, wherein the first location, the second location, the third location and the fourth location are on different limbs of the patient.
[0167] For any of the disclosed methods, including those using two medical devices, three medical devices, or four medical devices, in some embodiments, each medical device is positioned to initially drain a different lymph node, the draining lymph nodes being in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), or the like. The lymph nodes are selected from the group of lymph nodes found in the esophagus, esophageal, esophageal, and esophageal regions, including the esophageal, esophageal, and esophageal regions, including the esophageal, esophageal, and esophageal regions, including the esophageal, esophageal, and esophageal regions.
[0168] In one non-limiting example where three medical devices are used on a patient, a first device is placed on the patient's right forearm which then drains the right axillary lymph nodes, a second device is placed on the patient's left forearm which then drains the left axillary lymph nodes, and a third device is placed on the patient's left thigh which then drains the left inguinal lymph nodes, where the second and third devices both drain into the thoracic duct but into different initial draining lymph nodes.
[0169] In some embodiments, the first dose of the therapeutic agent, the second dose of the therapeutic agent, and, if present, the third dose of the therapeutic agent and the fourth dose of the therapeutic agent may each be administered to the patient sequentially or simultaneously. The doses may be combined such that the first and second doses are administered simultaneously, while the third and fourth doses are administered together, but sequentially with respect to the first and second doses. In some embodiments, the first and third doses are administered simultaneously, while the second and fourth doses are administered simultaneously with each other and sequentially with the first and third doses. In yet another embodiment, each dose is administered sequentially.
[0170] For any individual dose or combination of doses administered sequentially, there is a predetermined time between the start of each administration. This predetermined time may be 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 20 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours. The predetermined period of time may be about 15 minutes to about 72 hours, or any time increment therebetween. Each time is selected independently of any other time and is based on the medical needs of the patient and the assessment of the medical professional administering, monitoring, or directing the patient's treatment. Because the time it takes to administer a dose of a therapeutic agent using a medical device is not zero, the start of administration of a subsequent dose of a therapeutic agent may be before administration of the previous dose is completed. For example, administration of a second dose of a therapeutic agent may begin before administration of a first dose of a therapeutic agent is completed. In yet another embodiment, the predetermined time is based on the end of one dose and the start of the next dose.
[0171] In some embodiments, the anti-CTLA-4 antibody is imilimumab, a biosimilar thereof or a biological equivalent thereof. When two or more medical devices are used, the anti-CTLA-4 antibodies administered to the patient using the two or more devices may be the same or different.
[0172] In some aspects, the therapeutic agent is effective in treating or alleviating symptoms of an inflammatory medical condition. In some aspects, the therapeutic agent is an antibody that inhibits TNF-α. In some embodiments, the therapeutic agent is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, or a biosimilar or biological equivalent of any one of the aforementioned agents. In some embodiments, the therapeutic agent is etanercept, a biosimilar thereof, or a biological equivalent thereof. In some embodiments, the therapeutic agent is adalimumab, a biosimilar thereof, or a biological equivalent thereof. In some embodiments, the therapeutic agent is an immunosuppressant. In some embodiments, the immunosuppressant is adalimumab (Humira®), etanercept (Enbrel®), infliximab (Remicade®), ustekinumab (Stelara®), rituximab (Rituxan®), secukinumab (Cosentyx®), omalizumab (Xolair®), natalizumab (Tysabri®), ixekizumab (Taltz®), obinutuzumab (Gazyva®), or rituximab / hyaluronidase human (Rituxan Hycela™), or a biosimilar or bioequivalent of any of the foregoing.
[0173] In yet another embodiment, disclosed herein is a method for increasing the bioavailability of a therapeutic agent in a patient, the method comprising placing at least one medical device comprising a plurality of microneedles on a surface of the patient's skin, and administering the therapeutic agent to the patient via the at least one medical device.
[0174] In some embodiments, the method for delivering a therapeutic agent to a patient as described herein results in a comparable serum absorption rate of one or more therapeutic agents described herein compared to intravenous, subcutaneous, intramuscular, intradermal or parenteral delivery routes, while maintaining the relatively high rate of lymphatic delivery described herein. Without being bound by any theory, the increased delivery rate and bioavailability may be due to lymphatic circulation of one or more agents that enter the blood circulation through the thoracic duct or right lymphatic trunk. For measurement of serum concentrations at desired time points and treatment monitoring, standard, highly accurate and precise methods well known in the art, such as radioimmunoassay, high performance liquid chromatography (HPLC), fluorescence polarization immunoassay (FPIA), enzyme immunoassay (EMIT) or enzyme-linked immunosorbent assay (ELISA), may be used. To calculate the absorption rate using the above-mentioned method, the absorption rate is measured starting immediately after administration and then C max Drug concentrations should be measured at incremental time points until a value is established and the associated absorption rate calculated. IV. METHODS FOR TREATING CANCER AND / OR PREVENTING CANCER METASTASIS BY LYMPHATIC DELIVERY
[0175] In some embodiments, a method is provided for treating metastasis of a cancer in a patient. The method may include locating at least one lymph node of the patient that is interposed in the lymphatic system between a solid cancer tumor and a draining trunk, placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location under the patient's skin that is located between the interposed lymph node and the solid cancer tumor, the first location being adjacent to a lymphatic vessel and / or lymph capillary of the patient's lymphatic system, the microneedles having a surface that includes nanotopography, inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the first location, and administering a therapeutically effective amount of an anti-CTLA-4 antibody to the first location via the plurality of microneedles.
[0176] In yet another embodiment, a method for treating, preventing or reducing metastasis of cancer in a patient is disclosed herein. The method may include the steps of locating a solid cancer tumor in the patient, locating at least one lymph node in the patient that is intervening in the lymphatic system between the solid cancer tumor and the draining trunk, placing a medical device including a plurality of microneedles on the patient's skin at a first location on the patient's skin adjacent to lymphatic capillaries and / or lymphatic vessels that drain to the intervening lymph node, the microneedles having a surface that includes nanotopography, inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated, and administering a therapeutically effective amount of an anti-CTLA-4 antibody through the plurality of microneedles to the lymphatic capillaries and / or lymphatic vessels that drain to the intervening lymph node.
[0177] In some embodiments, a method of treating cancer in a patient is provided, the method comprising: placing a medical device including a plurality of microneedles on the patient's skin proximate to a first location under the patient's skin, the first location proximate to a lymphatic vessel and / or lymphatic capillary of the patient's lymphatic system, the microneedles having a surface including nanotopography, inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate to the first location, and administering an anti-CTLA-4 antibody through the plurality of microneedles to the first location, thereby treating the cancer.
[0178] In some embodiments, the methods disclosed herein that include a step of administering an anti-CTLA-4 antibody have any of the features described above with respect to methods of administering a therapeutic agent to the lymphatic system of a patient, including, for example, administration to first and second locations proximate lymphatic vessels and / or lymphatic capillaries that drain into the right lymphatic trunk and thoracic duct, respectively.
[0179] In some embodiments, the lymph node is a draining lymph node of the cancer. The draining lymph node of the cancer refers to the lymph node downstream of a solid cancer tumor, and is the first lymph node affected by the metastasis of the tumor. The first lymph node affected by the metastasis is often called the sentinel lymph node.
[0180] Since metastasis may be a systemic problem for the patient rather than a local one, in some embodiments, the medical device is placed in the patient to provide systemic delivery of the anti-CTLA-4 antibody, rather than just targeted delivery to a specific lymph node. In some embodiments, the device is placed so that the anti-CTLA-4 antibody can pass through one or more lymph nodes after administration, but does not target a specific lymph node. The medical device is placed with the expectation that the anti-CTLA-4 antibody will enter the patient's circulatory system after passing through the lymphatic system, resulting in systemic exposure to the anti-CTLA-4 antibody. This type of administration is intended to treat metastatic cancer cells that have passed the local environment of the primary solid cancer tumor. Such metastatic cancer cells may not yet show symptoms in the new location, but will eventually show symptoms if left untreated.
[0181] In yet another aspect, a method for treating a solid cancer tumor of a patient is disclosed herein. The method generally includes the steps of: locating a solid cancer tumor of the patient; locating a location of the patient's lymphatic system that is upstream of the solid cancer tumor; placing a medical device that includes a plurality of microneedles on the patient's skin adjacent to a first location under the patient's skin that is located adjacent to a location of the patient's lymphatic system that is upstream of the solid cancer tumor, the first location being adjacent to a lymphatic vessel and / or lymphatic capillary that is upstream of the solid cancer tumor, the microneedles having a surface that includes nanotopography; inserting the plurality of microneedles into the patient to a depth, thereby penetrating at least the epithelium; and administering a therapeutically effective amount of an anti-CTLA-4 antibody to the first location through the plurality of microneedles that is effective for preventing or reducing metastasis of the solid cancer tumor. In some aspects, the location of the patient's lymphatic system to which the therapeutic agent is delivered is downstream of the solid cancer tumor.
[0182] In some embodiments, administration is to a lymphatic vessel upstream of a solid cancer tumor. In other embodiments, administration is to both a lymph node and a lymphatic vessel upstream of a solid cancer tumor. In some aspects, it may not be necessary to locate a lymph node upstream of a tumor before administering an anti-CTLA-4 antibody to a patient. In some embodiments, the medical device is placed distal to the draining trunk to the solid cancer tumor. In yet another aspect, the medical device is proximal to the draining trunk to the solid cancer tumor.
[0183] Cancer and other medical conditions can damage a patient's lymphatic system, so that fluid flow in the lymphatic system can be poor or even reversed (called reflux). This can cause swelling in the patient's surrounding tissues and organs. In some embodiments, the medical device is positioned so that reflux in the lymphatic system transports the anti-CTLA-4 antibody to a targeted location. For example, in a properly functioning lymphatic system, a location downstream relative to a solid cancer tumor does not transport the anti-CTLA-4 antibody directly to the tumor. However, in a poor lymphatic system, reflux from a location downstream relative to a solid cancer tumor transports the anti-CTLA-4 antibody directly to the tumor. A medical professional skilled in the art understands how the lymphatic system works and makes patient treatment decisions based on that knowledge.
[0184] In some embodiments, the medical device is placed in the location of the patient's skin so that lymphatic vessels and / or lymphatic capillaries flow directly to the specifically targeted lymph node without first passing through solid cancer tumor or any other lymph node.In this case, the anti-CTLA-4 antibody enters the patient's lymphatic vessels after administration and flows directly to the targeted lymph node.In yet another embodiment, there may be lymph nodes between the administration site and the targeted lymph node.One non-limiting example of when this occurs is when the targeted lymph node is deep inside the patient's body and there is no lymphatic vessel near the patient's skin that flows directly to the targeted lymph node.
[0185] Certain types of cancers are known to often metastasize to specific lymph nodes, and placement of medical devices can be made on this basis. For example, in addition to head and neck cancers, oral and pharyngeal cancers metastasize to the jugular, cervical and supraclavicular lymph nodes, many skin cancers (e.g., melanoma) metastasize to the draining axillary and / or inguinal lymph node basins depending on the location of the cancer, breast cancer metastasizes to the axillary, internal mammary and supraclavicular lymph nodes, prostate cancer metastasizes to the lumbar, inguinal and peritoneal lymph nodes, brain and central nervous system cancers metastasize to the jugular, cervical and lumbar lymph nodes, ovarian cancer metastasizes to the retroperitoneal (pelvic and / or periaortic) lymph nodes, and cancers of the patient's reproductive tract metastasize to the lumbar, inguinal and peritoneal lymph nodes.
[0186] The specific lymph nodes targeted for delivery of the medicament are based on any reasonable criteria based on medical need and patient condition. For example, a lymph node biopsy may be performed to determine whether metastatic cancer cells are present in a particular lymph node. Alternatively, the lymph node may be selected based on its location in the patient's body relative to a previously located tumor. In some embodiments, the lymph node is selected because it is downstream of a solid cancer tumor. By placing the medical device in a position to target downstream lymph nodes, the metastatic cancer cells present in these lymph nodes are affected, reducing the possibility of them spreading to other parts of the body. Alternatively, the medical device may be placed upstream of the tumor to take advantage of tumor-induced lymphangiogenesis, which often occurs with solid cancer tumors. In this configuration, the medicament flows directly to the tumor, thereby more effectively targeting the tumor.
[0187] In some aspects, the amount of drug required to target metastatic cancer cells or tumors is lower than that given by other routes of administration. Lower doses, which are still therapeutically effective, may reduce or eliminate side effects and result in more positive patient outcomes.
[0188] In some embodiments, the anti-CTLA-4 antibody is imilimumab, its biosimilar, or its bioequivalent.When two or more medical devices are used, the anti-CTLA-4 antibody administered to the patient using the two or more medical devices can be the same or different.In yet another aspect, two medical devices containing multiple microneedles are used to administer a single anti-CTLA-4 antibody.In this case, each individual dose administered by each medical device may be lower than the therapeutically effective dose, but the combined dose administered by the two medical devices is therapeutically effective.
[0189] When the methods disclosed herein are used to treat solid cancer tumors or reduce or eliminate cancer metastasis, the cancer may be of any type that is susceptible to treatment with an anti-CTLA-4 antibody. Types of cancer include, but are not limited to, adenoid cystic carcinoma, adrenal tumor, amyloidosis, anal cancer, ataxia telangiectasia, atypical nevus syndrome, Beckwith-Wiedemann syndrome, cholangiocarcinoma, Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain tumor, breast cancer, carcinoid tumor, Carney complex, cervical cancer, colorectal cancer, ductal carcinoma, endometrial cancer, esophageal cancer, familial adenomatous polyposis, gastric cancer, gastrointestinal stromal tumor, islet cell tumor, juvenile polyposis syndrome, and Kaposi's sarcoma. (Kaposi's sarcoma), kidney cancer, laryngeal cancer, liver cancer, lobular carcinoma, lung cancer, small cell lung cancer Cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Lynch syndrome, malignant glioma, mastocytosis, melanoma, meningioma, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, multiple myeloma, myelodysplastic syndrome, nasopharyngeal cancer, neuroendocrine tumors, nevoid basal cell carcinoma syndrome, oral cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors, parathyroid cancer, penile cancer, peritoneal cancer, Peutz-Jeghers syndrome, pituitary tumors, pleuropulmonary blastoma, polycythemia vera, prostate cancer, renal cell carcinoma, retinoblastoma, salivary gland cancer, sarcoma, alveolar soft part sarcoma and cardiac sarcoma, Kaposi sarcoma, skin cancer, small bowel cancer, small intestine cancer, stomach cancer cancer, testicular cancer, thymoma, thyroid cancer, Turcot's syndrome, uterine (endometrial) cancer, vaginal cancer, von Hippel-Lindau disease, Wilms' tumor (childhood), xeroderma pigmentosum, and combinations thereof. In some embodiments, the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, lung cancer, small cell lung cancer, melanoma, oral cancer, pancreatic cancer, pancreatic neuroendocrine tumors, penile cancer, prostate cancer, renal cell carcinoma, stomach cancer, testicular cancer, thyroid cancer, uterine (endometrial) cancer, and vaginal cancer. will be done.
[0190] In some embodiments, administration of the anti-CTLA-4 antibody is directly to a lymph node, a lymphatic vessel, an organ that is part of the lymphatic system, or a combination thereof. In some embodiments, administration is to a lymph node. In some embodiments, administration is to a specific lymph node as described elsewhere herein. In yet other embodiments, administration is to a lymphatic vessel upstream of a specific lymph node that is known to drain to the specific lymph node. In yet other embodiments, administration is to a lymphatic vessel upstream of a solid cancer tumor that is known to drain to the solid cancer tumor.
[0191] It is understood that when multiple doses of an anti-CTLA-4 antibody are administered to a patient, each individual dose may not be therapeutically effective, but the combined dose will be therapeutically effective. The therapeutically effective combined dose may be lower than the therapeutically effective dose when the anti-CTLA-4 antibody is administered by a different route (e.g., subcutaneously, intravenously, etc.).
[0192] In some embodiments, delivery of anti-CTLA-4 antibodies to the lymphatic system is to the lymphatic duct system, lymph nodes described elsewhere herein, or both. In some aspects, delivery is to the superficial lymphatic vessels. In yet another aspect, delivery is to one or more lymph nodes. The particular target of delivery is based on the medical needs of the patient. In one non-limiting example, if a lymph node biopsy or other medical evaluation (e.g., lymphadenopathy) is found to be positive for possible metastatic cancer cells, a medical device including multiple microneedles may be placed in the patient to deliver anti-CTLA-4 antibodies directly to the lymph node. In another non-limiting example, a sentinel lymph node biopsy is performed, where the sentinel lymph node is selected based on the type of cancer and the medical professional's evaluation. Alternatively, the medical device may be placed upstream of a lymph node such that the anti-CTLA-4 antibody is delivered to a lymphatic vessel draining into the targeted lymph node. In some embodiments, two or more medical devices are used to target two or more different locations in the patient's lymphatic system. In another non-limiting example, the medical device is placed upstream of the solid cancer tumor so that anti-CTLA-4 antibody flows directly into the tumor. In another example, the medical device is placed directly downstream of the solid cancer tumor so that anti-CTLA-4 antibody passes through the same lymphatic vessel as metastatic cells. In yet another embodiment, one medical device is placed upstream of the solid cancer tumor and a second medical device is placed downstream of the solid cancer tumor. This effectively treats both the solid cancer tumor and any possible metastatic cells that have started to spread in the patient.
[0193] V. Methods for Treating Inflammatory Medical Conditions by Lymphatic Delivery
[0194] One embodiment disclosed herein is a method for treating inflammatory medical conditions in a patient.The method generally includes the steps of: determining at least one inflammation site in a patient, the at least one inflammation site includes lymphatic vessel, lymphatic capillary, lymph node, lymphatic organ, or any combination thereof; determining a first location in the patient's lymphatic system that is upstream of the inflammation site; placing a medical device that includes multiple microneedles on the patient's skin adjacent to the first location, the microneedles having a surface that includes nanotopography; inserting the multiple microneedles into the patient to a certain depth, thereby penetrating at least the epithelium; and administering a therapeutically effective amount of an antibody that inhibits TNF-α or etanercept or its biosimilar or biological equivalent through the multiple microneedles to the first location.
[0195] In another aspect, a method for reducing TNF-α levels in a patient is disclosed herein. The method generally includes the steps of locating a first location in the lymphatic system of a patient, placing a medical device including a plurality of microneedles on the patient's skin adjacent to the first location, the microneedles having a surface including nanotopography, inserting the plurality of microneedles into the patient to a depth, thereby penetrating at least the epithelium, and administering a therapeutically effective amount of an antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof to the first location through the plurality of microneedles.
[0196] In another aspect, a method for treating an inflammatory medical condition of a patient is disclosed herein.The method generally includes the steps of: locating at least one inflammatory site of a patient, including lymph node, lymphatic capillary, lymphatic vessel, lymphatic organ, or any combination thereof; placing a medical device comprising a plurality of microneedles on the patient's skin adjacent to a first location under the patient's skin, the first location being located to include a selected lymphatic capillary and / or lymphatic vessel that delivers lymph directly to the lymphatic system of the inflammatory site, the microneedles having a surface that comprises nanotopography; inserting the plurality of microneedles into the patient to a depth, thereby penetrating at least the epithelium; and administering a therapeutically effective amount of an antibody that inhibits TNF-α or etanercept or its biosimilar or biological equivalent to the selected lymphatic capillary and / or lymphatic vessel of the patient through the plurality of microneedles.
[0197] In some embodiments, a method for treating an inflammatory medical condition of a patient is provided. The method includes the steps of: placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location under the patient's skin, the first location being located to include lymphatic capillaries and / or lymphatic vessels that deliver lymph directly to the lymphatic system, and the microneedles having a surface including nanotopography; inserting the plurality of microneedles into the patient to a depth, thereby penetrating at least the epithelium; and administering an antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof to the patient's lymphatic capillaries and / or lymphatic vessels through the plurality of microneedles, thereby treating the inflammatory medical condition.
[0198] In some embodiments, the methods disclosed herein comprising administering an antibody that inhibits TNF-α or etanercept, or a biosimilar or biological equivalent thereof, have any of the features described above with respect to methods of administering a therapeutic agent to a patient's lymphatic system, including, for example, administration to first and second locations proximate lymphatic vessels and / or lymphatic capillaries that drain into the right lymphatic trunk and thoracic duct, respectively.
[0199] In some embodiments, the inflammatory medical condition is selected from the group consisting of Behcet's disease, sarcoidosis, rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, non-infectious uveitis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and combinations thereof. In some embodiments, the inflammatory medical condition is rheumatoid arthritis. In some embodiments, the inflammatory medical condition is psoriatic arthritis. In some embodiments, the inflammatory medical condition is plaque psoriasis. In some embodiments, the inflammatory medical condition is ulcerative colitis. In some embodiments, the inflammatory medical condition is Crohn's disease. The inflammatory medical condition may be acute or chronic.
[0200] The site of inflammation in a patient may be any location in a patient that exhibits signs of inflammation, including, but not limited to, redness, swelling, fluid retention, joint pain, joint stiffness, abnormal warmth in the area, and loss of joint function.
[0201] In some embodiments, administration is to a lymphatic vessel upstream of the site of inflammation. In other embodiments, administration is to both a lymph node and a lymphatic vessel upstream of the site of inflammation. In some aspects, it may not be necessary to locate a lymph node upstream of the site of inflammation before administering to a patient an antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof.
[0202] Some medical conditions can damage a patient's lymphatic system, causing poor or even reversed fluid flow in the lymphatic system (called reflux). This can cause swelling in the patient's surrounding tissues and organs. In some embodiments, the medical device is positioned such that reflux in the lymphatic system transports the antibody or etanercept or its biosimilar or biological equivalent that inhibits TNF-α to a targeted location. For example, in a properly functioning lymphatic system, a location downstream to the site of inflammation does not transport the antibody or etanercept or its biosimilar or biological equivalent that inhibits TNF-α directly to the site of inflammation. However, in a poor lymphatic system, reflux from a location downstream to the site of inflammation transports the antibody or etanercept or its biosimilar or biological equivalent that inhibits TNF-α directly to the site of inflammation. A medical professional skilled in the art understands how the lymphatic system works and makes patient treatment decisions based on that knowledge.
[0203] In some aspects, the site of inflammation is a joint, a lymph node, a lymphatic vessel, an organ that is part of the lymphatic system, or a combination thereof. In some aspects, the therapeutic target is a joint. In some aspects, the therapeutic target is a lymph node. In some aspects, the therapeutic target is a specific lymph node as described elsewhere herein.
[0204] In some embodiments, the site of inflammation is a joint selected from the group consisting of ankle joints, knee joints, hip joints, shoulder joints, elbow joints, metacarpophalangeal joints of the hand, metatarsophalangeal joints of the foot, wrist joints, neck joints, and combinations thereof. In some embodiments, the site of inflammation is a psoriatic lesion.
[0205] In some embodiments, the site of inflammation is the knee and the selected lymphatic capillaries and / or lymphatic vessels drain to a popliteal lymph node, hi some embodiments, the site of inflammation is the knee and relative to the knee, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0206] In some embodiments, the site of inflammation is the neck and the selected lymphatic capillaries and / or lymphatic vessels drain to a cervical lymph node, hi some embodiments, the site of inflammation is the neck and relative to the neck, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0207] In some embodiments, the site of inflammation is the shoulder and the selected lymphatic capillaries and / or lymphatic vessels drain to a thoracic lymph node, a supraclavicular lymph node, an axillary lymph node, or any combination thereof. In some embodiments, the site of inflammation is the shoulder and, relative to the shoulder, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0208] In some embodiments, the site of inflammation is an elbow and the selected lymphatic capillaries and / or lymphatic vessels drain to a medial epicondylar lymph node and / or a brachial lymph node. In some embodiments, the site of inflammation is an elbow and, relative to the elbow, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart.
[0209] In some embodiments, the site of inflammation is the hip joint and the selected lymphatic capillaries and / or lymphatic vessels drain to an inguinal lymph node and / or a pelvic lymph node. In some embodiments, the site of inflammation is the hip joint and the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart relative to the hip joint. In some embodiments, the site of inflammation is the hip joint and the selected lymphatic capillaries and / or lymphatic vessels are located proximal to the heart relative to the hip joint.
[0210] In some embodiments, the site of inflammation is a psoriatic lesion and the selected lymphatic capillaries share common lymphatic vessels and / or lymphatic capillaries directly adjacent to and / or within the psoriatic lesion. In some embodiments, the medical device is placed at a location on the patient's skin that has lymphatic capillaries and / or lymphatic vessels that drain directly to lymph nodes located within and / or closest to the psoriatic lesion.
[0211] In some embodiments, when two medical devices containing multiple microneedles are used, the first medical device administers a first antibody or etanercept or a biosimilar or biological equivalent thereof that inhibits TNF-α to selected lymphatic capillaries and / or lymphatic vessels that are distal to the heart relative to the site of inflammation, and the second medical device administers a second antibody or etanercept or a biosimilar or biological equivalent thereof that inhibits TNF-α to selected lymphatic capillaries and / or lymphatic vessels that are proximal to the heart relative to the site of inflammation. In some embodiments, the first therapeutic agent and the second therapeutic agent are the same. In some embodiments, the first therapeutic agent and the second therapeutic agent are different. In this case, each individual dose administered by each medical device may be lower than the therapeutically effective dose, but the combined dose administered by the two medical devices is therapeutically effective.
[0212] In some embodiments, the delivery of the antibody or etanercept or its biosimilar or biological equivalent that inhibits TNF-α to the lymphatic system is to the lymphatic system, to a lymph node as described elsewhere herein, or both. In some aspects, the delivery is to the superficial lymphatic vessels. In yet another aspect, the delivery is to one or more lymph nodes. The specific target of the delivery is based on the medical needs of the patient. In one non-limiting example, if a patient's joint shows signs of a flare-up of acute arthritis associated with a chronic arthritic condition, a medical device comprising multiple microneedles may be placed in the patient to deliver the antibody or etanercept or its biosimilar or biological equivalent that inhibits TNF-α directly to that specific joint. Alternatively, the medical device may be placed upstream of the joint so that the antibody or etanercept or its biosimilar or biological equivalent that inhibits TNF-α is delivered to a lymphatic vessel that drains into the targeted joint. In some embodiments, two or more medical devices are used to target two or more different locations in the patient's lymphatic system.
[0213] The placement of the medical device is based on the patient's medical condition and / or the medical professional's evaluation.In one non-limiting example, in a patient suffering from acute flare-ups of rheumatoid arthritis in one specific joint (e.g., knee or shoulder), the medical device is placed upstream to deliver drugs to the lymphatic vessels that flow and / or go to the inflamed joint, so as to more effectively target the specific location of the acute flare-up.Similarly, in another non-limiting example, a patient with multiple patches of psoriasis lesions may have two or more medical devices placed in different locations on the body upstream of the lesions, so as to more precisely target the specific lesions.
[0214] In some aspects, the antibody that inhibits TNF-α or etanercept or its biosimilar or biological equivalent is effective in treating or alleviating the symptoms of an inflammatory medical condition. In some embodiments, the antibody that inhibits TNF-α or etanercept or its biosimilar or biological equivalent is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, or a biosimilar or biological equivalent of any of the aforementioned agents. In some embodiments, the therapeutic agent is etanercept, its biosimilar or biological equivalent. In some embodiments, the therapeutic agent is adalimumab, its biosimilar or biological equivalent.
[0215] It is understood that when multiple doses of a therapeutic agent are administered to a patient, each individual dose may not be therapeutically effective, but the combined dose will be therapeutically effective. A therapeutically effective combined dose may be lower than the therapeutically effective dose of the same therapeutic agent when administered by a different route (e.g., subcutaneous, intravenous, etc.). VI. Medical Devices
[0216] Medical devices containing arrays of microneedles suitable for use herein are known in the art. Certain exemplary structures and devices including means for controllably delivering one or more agents to a patient are described in International Patent Application Publication Nos. WO2014 / 188343, WO2014 / 132239, WO2014 / 132240, WO2013 / 061208, WO2012 / 046149, WO2011 / 135531, WO2011 / 135530, WO2011 / 135533, WO2014 / 132240, WO2015 / 16821, and International Patent Application Nos. PCT / US2015 / 028154 (WO2015 / 168214), and in US Pat. A1), PCT / US2015 / 028150 (published as WO2015 / 168210 A1), PCT / US2015 / 028158 (published as WO2015 / 168215 A1), PCT / US2015 / 028162 (published as WO2015 / 168217 A1), PCT / US2015 / 028164 (published as WO2015 / 168219 A1), PCT / US2015 / 038231 (published as WO2016 / 003856 A1), PCT / US2015 / 038232 (published as WO2016 / 003857 A1), PCT / US2016 / 043623 (published as WO2017 / 019526 A1), PCT / US2016 / 043656 (published as WO2017 / 019535 A1), PCT / US2017 / 027879 (published as WO2017 / 189258 A1), PCT / US2017 / 027891 (published as WO2017 / 189259 A1), PCT / US2017 / 064604 (published as WO2018 / 111607 No. 5,393,991, PCT / US2017 / 064609 (published as WO2018 / 111609 A1), PCT / US2017 / 064614 (published as WO2018 / 111611 A1), PCT / US2017 / 064642 (published as WO2018 / 111616 A1), PCT / US2017 / 064657 (published as WO2018 / 111620 A1), and PCT / US2017 / 064668 (published as WO2018 / 111621 A1), all of which are incorporated by reference in their entireties.
[0217] In some aspects of the embodiments described herein, the one or more therapeutic agents are administered by applying one or more medical devices to one or more sites of the patient's skin.One non-limiting example of a medical device that includes multiple microneedles and is suitable for use with any of the methods disclosed herein is the Sofusa™ drug delivery platform available from Sorrento Therapeutics, Inc.
[0218] In some embodiments, the medical device is placed in direct contact with the patient's skin. In some embodiments, there is an intervening layer or structure between the patient's skin and the medical device. For example, surgical tape or gauze may be used to reduce possible skin irritation between the medical device and the patient's skin. When the microneedles extend from the device, they contact, and in some cases penetrate, the epidermis or dermis of the patient to deliver the medicament to the patient. The delivery of the medicament can be to the circulatory system, lymphatic system, interstitial, subcutaneous, intramuscular, intradermal, or a combination thereof. In some embodiments, the medicament is delivered directly to the patient's lymphatic system. In some aspects, the medicament is delivered to the superficial lymphatic vessels of the lymphatic system.
[0219] The term "proximate" as used herein is intended to encompass placement at and / or near a desired therapeutic target. By placing a medical device in proximity to a therapeutic target, an administered therapeutic agent enters the lymphatic system and passes through to the intended therapeutic target. Additionally, the placement of the medical device may be such that an administered therapeutic agent is administered directly to the therapeutic target.
[0220] In some embodiments described herein, a method including a medical device including a plurality of microneedles may include delivering one or more agents by a device including two or more delivery structures capable of penetrating the stratum corneum of a patient's skin, and obtaining a delivery depth and volume of the skin to controllably deliver one or more agents at a dosing rate as described herein. The delivery structures may be attached to an underlying substrate of the medical device and may be arranged at one or more different angles to deliver one or more agents through the stratum corneum. In some aspects described herein, the underlying substrate including the delivery structures may contact the patient's skin and may have a cylindrical, rectangular, or geometrically irregular shape. The underlying substrate may be about 1 mm thick in some aspects. 2 ~ approx. 10,000mm 2In some embodiments, the delivery structures may include any geometric shape (e.g., cylindrical, rectangular, or geometrically irregular). Additionally, the delivery structures may include a length and a cross-sectional area. In some embodiments, the delivery structures may have a total length that is greater than the cross-sectional diameter or width. In some other embodiments, the delivery structures may have a cross-sectional diameter or width that is greater than the total length. In some embodiments, the cross-sectional width of each of the delivery structures may be from about 5 μm to about 140 μm, inclusive of each integer within the specified range, and the cross-sectional area may be about 25 μm. 2 ~about 65,000μm 2 In some embodiments, the length of each of the delivery structures may be from about 10 μm to about 5,000 μm, from about 50 to about 3,000 μm, from about 100 to about 1,500 μm, from about 150 to about 1,000 μm, from about 200 to about 800 μm, from about 250 to about 750 μm, or from about 300 to about 600 μm. In some aspects, the length of each of the delivery structures may be from about 10 μm to about 1,000 μm, including each integer within the specified range. Surface areas and cross-sectional areas described herein may be determined using standard geometric calculations known in the art.
[0221] The delivery structures described herein do not have to be identical to each other. A medical device having multiple delivery structures may each have a different length, outer diameter, inner diameter, cross-sectional shape, nanotopographic surface, and / or spacing between each delivery structure. For example, the delivery structures may be evenly spaced, such as in a rectangular or square grid or concentric circles. The spacing may depend on a number of factors, including the height and width of the delivery structure, and the amount and type of drug intended to be delivered by the delivery structure. In some embodiments, the spacing between each delivery structure may be about 1 μm to about 1500 μm, including each integer within the specified range. In some embodiments, the spacing between each delivery structure can be about 200 μm, about 300 μm, about 400 μm, about 500 μm, about 600 μm, about 700 μm, about 800 μm, about 900 μm, about 1000 μm, about 1100 μm, about 1200 μm, about 1300 μm, about 1400 μm, or about 1500 μm. As used in this context, "about" means ±50 μm.
[0222] In some embodiments described herein, the medical device may include a needle array in the form of a patch. In some aspects, the needle array can penetrate the most superficial layer of the stratum corneum and first deliver one or more agents described herein to at least a portion or all of the non-viable epithelium, at least a portion or all of the viable epithelium, and / or at least a portion of the viable dermis of a subject, and then to the lymphatic system of the patient. These needles may further include nanotopography on the surface of the needle, in a random or organized pattern. In some aspects, the pattern of nanotopography may exhibit a fractal geometry.
[0223] In some embodiments, the delivery structure may include an array of needles in fluid communication with a liquid carrier vehicle containing one or more agents. In some aspects, the needles are microneedles. In some aspects, the array of needles may include 2-50,000 needles having structural means for controlling penetration of the skin and fluid delivery to the skin (e.g., penetrating and delivering to the skin). See, for example, International Patent Application PCT / US2017 / 064668 (published as WO2018 / 111621 A1), which is incorporated herein by reference in its entirety. In some other aspects, the array of needles may further include random or structured nanotopography fabricated on each needle. The needle or needle array may be mounted on a larger drug delivery device that includes a fluid delivery rate control means, an adhesive for mounting to the skin, a fluid pump, etc. If desired, the delivery rate of the agent may be variably controlled by a pressure generation means. The desired delivery rates described herein to the epithelium can be effected by driving one or more of the agents described herein through application of pressure or other driving means including pumps, syringes, pens, elastomeric membranes, gas pressure, piezoelectric, electric, electromagnetic or osmotic pumping, or using rate controlling membranes, or by combinations thereof.
[0224] FIG. 13 is a cross-sectional view of one illustrative example of a medical device (e.g., a pharmaceutical delivery device) including multiple microneedles, generally designated 10, in a pre-use configuration. It is understood that this example is suitable for use with all embodiments and aspects of the subject matter disclosed herein. Other devices known in the art are also suitable for use with the present specification. FIG. 14 is a cross-sectional view of the fluid delivery device 10 in a use configuration. FIG. 15 is an exploded cross-sectional view of the fluid delivery device 10. In the illustrative embodiment, the fluid delivery device 10 includes multiple sub-assembly components that couple together to form the fluid delivery device 10, including a collet assembly 12 and a fluid distribution assembly 14. The collet assembly 12 and the fluid distribution assembly 14 are generally designated by their respective reference numbers. As shown in FIG. 15, the fluid distribution assembly 14 includes multiple additional sub-assembly components, including a plenum assembly 16, a cartridge assembly 18, a cap assembly 320, and a machine controller assembly 20. Each of the collet assembly 12, fluid distribution assembly 14, plenum assembly 16, cartridge assembly 18, cap assembly 320 and mechanical controller assembly 20 are generally designated by their respective reference numerals in the accompanying drawings. The collet assembly 12 forms the body or housing of the fluid delivery device 10 and is slidably coupled to the fluid distribution assembly 14. The cap assembly 320 is coupled to the cartridge assembly 18, which is slidably coupled to the plenum assembly 16 to form the fluid distribution assembly 14. Additionally, the mechanical controller assembly 20, which will be described in more detail below, is coupled to the cartridge assembly 18.
[0225] FIG. 16 is a cross-sectional view of the collet assembly 12 of the fluid delivery device 10, and FIG. 17 is an exploded perspective view. With reference to FIGS. 15-17, in an exemplary embodiment, the collet assembly 12 includes a collet 22 coupled to a collet lock 50. In an exemplary embodiment, the collet 22 is formed in a generally frusto-conical shape having a hollow interior space 24 defined therein. The collet 22 is formed generally symmetrically about a central axis "A." An upper edge 26 of the collet 22 defines an opening 28 to the interior space 24. A cylindrical upper wall 30 extends generally perpendicularly downward from the upper edge 26 of the collet 22 toward a central portion 32. A lower wall 34 extends downward at an outward angle from the central portion 32 of the collet 22 toward a base 36 (or lower end) thereof. The upper wall 30, the central portion 32, and the lower wall 34 collectively define the interior space 24. The step 38 extends around the upper wall 30 and defines an outer horizontal surface 40 (or ledge) configured to engage a mounting band. The step 38 also defines an inner horizontal surface 42 (or step) configured to engage the plenum assembly 16 to facilitate proper positioning of the plenum assembly 16 above the skin surface of a user prior to use of the fluid delivery device 10.
[0226] 17, the collet 22 includes a pair of notches, generally indicated at 44, opposed to one another and formed through the lower wall 34. In an exemplary embodiment, the notches 44 are generally rectangular in shape and configured to receive a portion of the collet lock 50. Additionally, the collet 22 includes one or more stops 46 configured to facilitate positioning of the collet lock 50 when coupled to the collet 22. For example, and without limitation, the one or more stops 46 are formed as inwardly extending protrusions formed in the lower wall 34. The stops 46 may have any form or shape that enables the stops 46 to function as described herein.
[0227] 16 and 17, the collet 22 includes a plurality of flexible tabs 48 integrally formed with the upper wall 30. Further, the plurality of flexible tabs 48 are positioned about and equidistant from a central axis "A". In particular, the plurality of flexible tabs 48 extend from a first end 76 to an opposing second free end 78. In an exemplary embodiment, the second free end 78 is configured to bend radially inward and engage the plenum assembly 16 to facilitate proper positioning of the plenum assembly 16 against a user's skin surface during use of the fluid delivery device 10.
[0228] As illustrated in FIGS. 16 and 17, in the exemplary embodiment, the collet lock 50 is generally annular and has a convex inner surface 52 that extends from a lower outer end 54 of the collet lock 50 to a generally cylindrical inner wall 56. The inner wall 56 extends upwardly to an upper surface 58. The collet lock 50 includes a generally cylindrical outer wall 60 that is concentric with the inner wall 56 and extends upwardly from the lower outer end 54. Additionally, the collet lock 50 includes latching members 62, 64 that oppose each other and extend upwardly from the upper surface 58. The latching members 62, 64 are configured to couple to the notches 44 of the collet 22. The latching member 62 includes a first connecting member 66 that extends outwardly from the latching member 62. In particular, the first connecting member 66 includes a neck 63 that extends at a substantially vertical upward angle to the lower wall 34 of the collet 22. Additionally, the first connecting member 66 includes a head 65 that extends generally parallel to the lower wall 34 beyond the periphery of the neck 63. Additionally, the first connecting member 66 includes a window or aperture 61 that extends through the head 65. The window 61 is configured to provide an indication to a user of the fluid delivery device 10 regarding the tightness of the mounting band 430, as described further herein.
[0229] Similarly, the latching member 64 includes a pair of adjacent second connecting members 68 extending outwardly from the latching member 64. In the exemplary embodiment, the connecting members 68 each include a neck 67 that extends at a substantially vertical upward angle to the lower wall 34 of the collet 22. Additionally, the second connecting members 68 include a head 69 that extends generally parallel to the lower wall 34 beyond the periphery of the neck 67. The first connecting member 66 and the pair of second connecting members 68 are configured to engage the mounting band 430, as described further herein.
[0230] In the exemplary embodiment, the outer wall 60 of the collet lock 50 includes an upper outer surface 70 that slopes inwardly at an angle substantially parallel to the lower wall 34 to facilitate direct engagement with the lower wall 34. Additionally, the upper surface 58 includes a plurality of stop members 72 extending upwardly and configured to engage one or more stops 46 of the collet 22 to facilitate proper positioning of the collet lock 50 when coupled to the collet 22. Extending radially inwardly from the convex inner surface 52 are a plurality of tabs 74 configured to engage the plenum assembly 16 to facilitate proper positioning of the plenum assembly 16 against a user's skin surface during use of the fluid delivery device 10.
[0231] In an exemplary embodiment, the collet 22 couples to the collet lock 50 to form a unitary assembly (shown in FIG. 16 ). In particular, the upper surface 70 and latching members 62, 64 of the collet lock 50 engage the lower wall 34 and notch 44 of the collet 22 via a permanent coupling method, such as, but not limited to, an adhesive bond, a welded joint (e.g., spin welding, ultrasonic welding, laser welding, or heat staking), or the like. Alternatively, the collet 22 and collet lock 50 may be coupled together using any connection technique that allows for the formation of the collet assembly 12.
[0232] Further description of the fluid delivery device 10 seen in Figures 13-17, including its operation, can be found in PCT / US2017 / 064668 (published as WO2018 / 111621 A1), which is incorporated by reference in its entirety.
[0233] In some embodiments described herein, the medical device comprising a plurality of microneedles described herein can function as a permeability enhancer and increase the delivery of one or more agents through the epithelium. This delivery can occur by modulating transcellular transport mechanisms (e.g., active or passive mechanisms) or by paracellular permeation. Without being bound by any theory, the nanostructured or nanotopographical surface can increase the permeability of one or more layers of the viable epithelium, including the epithelial basement membrane, by modifying cell / cell tight junctions to allow modification of paracellular or cell active transport pathways (e.g., transcellular transport) and allowing diffusion or migration and / or active transport of the administered agent through the viable epithelium and into the underlying viable dermis. This effect may be due to modulation of gene expression of cell / cell tight junction proteins. As previously mentioned, tight junctions are found in viable skin, particularly in viable epithelium. Opening of tight junctions can provide a paracellular route to improve the delivery of any agent, such as an agent that was previously blocked from delivery through the skin.
[0234] Interaction between individual cells and nanotopographical structures may increase the permeability of epithelial tissue (e.g., epithelium), induce the passage of drugs through barrier cells, and enhance transcellular transport. For example, interaction with viable epithelial keratinocytes may enhance distribution of drugs to the keratinocytes (e.g., transcellular transport) followed by diffusion through the cells and across the lipid bilayer again. Furthermore, interaction of nanotopographical structures with keratinocytes of the stratum corneum may induce changes in barrier lipids or corneodesmosomes, allowing drugs to diffuse through the stratum corneum to the underlying viable epithelial layer. Drugs may cross the barrier by paracellular and transcellular routes, but the predominant transport route may vary depending on the nature of the drug.
[0235] In some embodiments described herein, the device may interact with one or more components of epithelial tissue, increasing the porosity of the tissue and rendering the tissue susceptible to paracellular and / or transcellular transport mechanisms. Epithelial tissue is one of the major tissue types of the body. Epithelial tissues that may be made more porous may include both simple and stratified epithelia, including both cornified and transitional epithelia. Additionally, epithelial tissues encompassed herein may include any cell type of the epithelial layer, including, but not limited to, keratinocytes, endothelial cells, lymphatic endothelial cells, squamous epithelial cells, columnar cells, cuboidal cells, and pseudostratified cells. Any method of measuring porosity may be used, including, but not limited to, any epithelial permeability assay. For example, whole mount permeability assays may be used to measure epithelial (e.g., skin) porosity or barrier function in vivo. See, for example, Indra and Leid., Methods Mol Biol. (763) 73-81, the teachings of which are incorporated herein by reference.
[0236] In some embodiments described herein, the structural changes induced by the presence of nanotopography surface on barrier cells are temporary and reversible. Surprisingly, it has been found that the use of nanostructured nanotopography surface can cause a temporary and completely reversible increase in epithelial tissue porosity by changing junction stability and dynamics, which, without being bound by any theory, can result in a temporary increase in paracellular and transcellular transport of administered drugs through the epithelium and into the viable dermis. Thus, in some aspects, the increase in permeability of epithelium or epithelial tissue caused by nanotopography, such as the promotion of paracellular or transcellular diffusion or movement of one or more drugs, returns to the normal physical state that existed before the epithelial tissue contacts the nanotopography after the removal of the nanotopography. In this way, the normal barrier function of barrier cells (e.g., epithelial cells) is restored, and no further diffusion or movement of molecules occurs beyond the normal physical diffusion or movement of molecules in the tissue of interest.
[0237] These reversible nanotopography-induced structural changes may function to limit secondary skin infections, absorption of harmful toxins, and limit dermal irritation. Also, the progressive reversal of epithelial permeability from the top to the basal layers of the epithelium may facilitate the movement of one or more agents through the epithelium and downward into the dermis, and impede the backflow or back diffusion of one or more agents back into the epithelium.
[0238] In some embodiments, methods are described herein for applying a device having multiple microneedles to the surface of a subject's skin for the treatment of a disease or disorder described herein. In some aspects, the device is applied to an area of the subject's skin, where the location of the body's skin is densely populated with lymphatic capillaries and / or blood capillaries. Multiple devices may be applied to one or more locations of the skin that have a dense network of lymphatic capillaries. In some aspects, one, two, three, four, five or more devices may be applied. The devices may be applied spatially separated or in close proximity or parallel to each other. Exemplary and non-limiting locations with dense lymphatic vessels include the palmar surface of the hand, the scrotum, the plantar surface of the foot, and the lower abdomen. The location of the device is selected based on the patient's medical condition and the evaluation of a medical professional.
[0239] In some embodiments described herein, at least a portion or all of the therapeutic agent may be delivered or administered directly to the skin, including non-viable epithelium and / or viable epithelium, to an initial depth. In some aspects, a portion of the therapeutic agent may also be delivered directly to the viable dermis in addition to the epithelium. The range of delivery depth depends on the medical condition being treated and the physiology of the skin of a given patient. This initial depth of delivery may be defined as the location in the skin where the therapeutic agent first comes into contact as described herein. Without being bound by any theory, it is believed that the administered agent may migrate (e.g., diffuse) from the initial delivery site (e.g., non-viable epithelium, viable epithelium, viable dermis, or stroma) to a deeper location in the viable skin. For example, a portion or all of the administered agent may be delivered to the non-viable epithelium and then continue to migrate (e.g., diffuse) into the viable epithelium, past the basal layer of the viable epithelium, and into the viable dermis. Alternatively, some or all of the administered agent may be delivered to the viable epidermis (i.e., just below the stratum corneum) and then continue to move (e.g., diffuse) past the basal layer of the viable epidermis and into the viable dermis. Finally, some or all of the administered agent may be delivered to the viable dermis. The movement of one or more active agents through the skin is multifactorial and depends, for example, on the lipid carrier composition (e.g., its viscosity), the administration rate, the delivery structure, etc. This movement through the epidermis and into the dermis may be further defined as a transport phenomenon and may be quantified by mass transfer rate and / or fluid dynamics (e.g., mass flow rate).
[0240] Thus, in some embodiments described herein, the therapeutic agent may be delivered to a depth of the epithelium, where the therapeutic agent passes through the basal layer of the viable epithelium and enters the viable dermis. In some aspects described herein, the therapeutic agent is then absorbed by one or more susceptible lymphatic capillary plexuses and delivered to one or more lymph nodes and / or lymphatic vessels.
[0241] In some embodiments described herein, the depth distribution of the skin where a portion of the one or more agents is delivered first, thereby allowing uptake of the one or more therapeutic agents by one or more susceptible tumors or inflammatory sites, or by lymphatic vessels draining the tumor or inflammatory sites, ranges from about 5 μm to about 4,500 μm. The thickness of the skin may vary from patient to patient based on a number of factors, including, but not limited to, medical condition, diet, sex, age, body mass index, and part of the body, and therefore the depth required to deliver the therapeutic agent varies. In some embodiments, the delivery depth is about 50 μm to about 4000 μm, about 100 to about 3500 μm, about 150 μm to about 3000 μm, about 200 μm to about 3000 μm, about 250 μm to about 2000 μm, about 300 μm to about 1500 μm, or about 350 μm to about 1000 μm. In some embodiments, the delivery depth is about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 250 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, about 500 μm, about 600 μm, about 700 μm, about 800 μm, about 900 μm, or about 1000 μm. As used in this context, "about" means ±50 μm.
[0242] In some embodiments described herein, the therapeutic agent may be delivered by a liquid carrier solution. In one aspect, the osmotic pressure of the liquid carrier may be hypertonic with respect to the fluid in the blood capillary or lymphatic capillary. In another aspect, the osmotic pressure of the liquid carrier solution may be hypotonic with respect to the fluid in the blood capillary or lymphatic capillary. In another aspect, the osmotic pressure of the liquid carrier solution may be isotonic with respect to the fluid in the blood capillary or lymphatic capillary. The liquid carrier solution may further comprise at least one or more pharma- ceutically acceptable excipients, diluents, cosolvents, particulates or colloids. Pharmaceutically acceptable excipients used in liquid carrier solutions are known, see, for example, Pharmaceutics: Basic Principles and Application to Pharmacy Practice (Alekha Dash et al. eds., 1st ed. 2013), the teachings of which are incorporated herein by reference.
[0243] In some embodiments described herein, the therapeutic agent is present in the liquid carrier as a substantially dissolved solution, suspension, or colloidal suspension. Any suitable liquid carrier solution that meets at least the specifications of the United States Pharmacopeia (USP) may be utilized, and the osmolality of such solutions may be modified as known. See, for example, Remington: The Science and Practice of Pharmacy (Lloyd V. Allen Jr. ed., 22nd ed. 2012). Examples Suitable non-limiting liquid carrier solutions may be aqueous, semi-aqueous or non-aqueous depending on the bioactive agent to be administered. For example, aqueous liquid carriers may include any one or combination of water and water-miscible vehicles, ethyl alcohol, liquid (low molecular weight) polyethylene glycols, and the like. Non-aqueous carriers may include fixed oils such as corn oil, cottonseed oil, peanut oil, or sesame oil. Suitable liquid carrier solutions may further include any one of preservatives, antioxidants, complexation enhancers, buffers, acidifiers, saline, electrolytes, viscosity enhancers, viscosity reducing agents, alkalizing agents, antibacterial agents, antifungal agents, solubility enhancers, or combinations thereof.
[0244] In some embodiments described herein, the therapeutic agent is delivered to viable skin, and the depth distribution of the viable skin for delivery of the agent is just past the stratum corneum of the epidermis, but above the subcutaneous tissue, which allows the agent to be taken up by the patient's lymphatic system. In some aspects, the depth of the viable skin for delivery of one or more agents ranges from about 1 μm to about 4,500 μm beyond the stratum corneum, but still within the viable skin above the subcutaneous tissue.
[0245] Non-limiting tests for evaluating the initial delivery depth of the skin may be invasive (e.g., biopsy) or non-invasive (e.g., imaging). Conventional non-invasive optical methods, including diffuse reflectance spectroscopy, fluorescence spectroscopy, photothermal conversion spectroscopy or optical coherence tomography (OCT), may be used to evaluate the delivery depth of the drug into the skin. Imaging using the method may be performed in real time to evaluate the initial delivery depth. Alternatively, an invasive skin biopsy may be performed immediately after administration of the drug, followed by standard histological and staining methods to determine the delivery depth of the drug. For examples of optical imaging methods useful for determining the skin penetration depth of an administered agent, see Sennhenn et al., Skin Pharmacol. 6(2) 152-160 (1993), Gotter et al., Skin Pharmacol. Physiol. 21 156-165 (2008), or Mogensen et al., Semin. Cutan. See Med. Surg 28 196-202 (2009).
[0246] In some embodiments, methods are described herein for long-term delivery (or administration) of the therapeutic agents described herein. A medical device comprising a plurality of microneedles is configured such that the flow rate of the medicament from the device to the patient is adjustable. Thus, the length of time required varies accordingly. In some aspects, the flow rate of the medical device is adjusted such that the medicament is administered for about 0.5 hours to about 72 hours. In some aspects, the administration time is about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 15 hours, 18 hours, 21 hours, 24 hours, 27 hours, 30 hours, 33 hours, 36 hours, 39 hours, 42 hours, 45 hours, 48 hours, 51 hours, 54 hours, 57 hours, 60 hours, 63 hours, 66 hours, 69 hours, or 72 hours. In other aspects, the administration time is selected based on the medical condition of the patient and an evaluation by the medical professional treating the patient.
[0247] In some embodiments described herein, one or more agents in liquid carrier solution are administered to an initial contiguous volume of the space under the outer surface of the skin.The one or more therapeutic agents in liquid carrier solution that are initially delivered to the skin (e.g., prior to subsequent migration or diffusion) may be distributed within or surrounded by the contiguous three-dimensional volume of the skin.The one or more agents that are initially delivered exhibit a Gaussian distribution of delivery depth and further have a Gaussian distribution within the three-dimensional volume of skin tissue.
[0248] In some embodiments described herein, the flow rate of a therapeutic agent into the skin per microneedle described herein may be from about 0.01 μl per hour to about 500 μl per hour. In some aspects, the flow rate of each individual microneedle is from about 0.1 μl per hour to about 450 μl per hour, from about 0.5 μl per hour to about 400 μl per hour, from about 1.0 μl per hour to about 350 μl per hour, from about 5.0 μl per hour to about 300 μl per hour, from about 5.0 μl per hour to about 250 μl per hour, from about 10 μl per hour to about 200 μl per hour, from about 15 μl per hour to about 100 μl per hour, or from about 20 μl per hour to about 50 μl per hour. In some embodiments, the flow rate of each individual microneedle is about 1 μl per hour, 2 μl per hour, 5 μl per hour, 10 μl per hour, 15 μl per hour, 20 μl per hour, 25 μl per hour, 30 μl per hour, 40 μl per hour, 50 μl per hour, 75 μl per hour, or 100 μl per hour. Each individual microneedle has a flow rate that contributes to the total device flow rate. The maximum total flow rate is the flow rate of each individual microneedle multiplied by the total number of microneedles. The total controlled flow rate of all combined microneedles may be about 0.2 μl per hour to about 50,000 μl per hour. The medical device is configured such that the flow rate can be appropriately controlled. The flow rate is based on the patient's medical condition and an assessment by the medical professional treating the patient.
[0249] EXAMPLES
[0250] Example 1 Pharmacokinetics of etanercept
[0251] Some methods and procedures for these experiments were adapted from Aldrich, et al., Arthritis Res. Ther., (2017), 19:116 (DOI 10.1186 / s13075-017-1323-z; Open Access), which is incorporated by reference in its entirety for all purposes.
[0252] To characterize the differences in etanercept delivery by different routes of administration, normal rats were used to determine the PK profile after delivery of a single dose of 1 mg etanercept in 100 μL via Sofusa™ (n=6), conventional IV (into the tail vein, n=6), SC (dorsolateral injection at the same site as application of Sofusa™, n=4) or ID injection (symmetrical dorsolateral injections 2×50 uL for a total dose of 1 mg etanercept, n=6). All administrations were performed using a 31-gauge needle, except for Sofusa™ delivery. At 2, 4, 8, 12, 24 and 36 hours after administration, animals were anesthetized with isoflurane and 200 μL of blood was collected from the jugular vein. Serum concentrations of etanercept were quantified using the Etanercept ELISA Kit (ABIN:1540251) (Matriks Biotechnology Co.,LTD., Ankara, Turkey). Optical density at 450 nm was measured using a Thermo Scientific Multiskan EX (Thermo Fisher Scientific, Waltham, MA, USA).
[0253] To determine the amount of etanercept delivered to the lymph nodes, solutions of radiolabeled etanercept were administered using the Sofusa™ drug delivery platform (1 mg etanercept in 100 μL), IV (1 mg etanercept in 100 μL into the tail vein), SC (1 mg etanercept, 100 μL into the dorsolateral side at the same site as the Sofusa™ application) and ID (1 mg etanercept total in two 50 μL injections). Animals were harvested at 12 and 36 hours post-dose and left / right axillary and inguinal lymph nodes were collected, weighed and counted for radioactivity using a 2480 Wizard2 automated gamma counter (PerkinElmer, Waltham, MA, USA). The time-corrected radioactivity was then used to calculate tissue concentrations of etanercept in μg / mL from the specific radioactivity of the dosing solution, and animals were euthanized at 12 hours (n=4, Sofusa™; n=6, IV; n=6, ID; and n=6, SC) and 36 hours (n=6, Sofusa™; n=6, IV; n=6, ID; and n=6, SC).
[0254] To verify the amount of etanercept delivered, the radioactivity in the Sofusa™ device and tubing was measured 1 hour before and 1 hour after injection. Measurements were performed using a dose calibrator. The amount of etanercept delivered was determined as the difference in time-corrected radioactivity before and after administration.
[0255] To directly visualize Sofusa™ delivery, 100 μL of 645 μM indocyanine green (ICG) (Akorn, Inc) in sterile saline was delivered over 1 h using a syringe pump (model NE-300, SyringePump.com) connected to a Sofusa™ applied to the right dorsal surface of the rat. NIRF imaging was performed.
[0256] In vivo bioavailability and biodistribution studies of etanercept in both rat and pig models demonstrated a pharmacokinetic profile that was significantly superior in many respects to subcutaneous injection and comparable to intravenous administration.
[0257] Results in Sprague-Dawley rats
[0258] As summarized in Tables 1 and 2 and shown in Figure 2, subcutaneous (SC) administration of etanercept demonstrated significantly inferior results compared to administration via the Sofusa™ drug delivery platform. max is significantly shorter, while C max was long. AUC 48 was nearly doubled using the Sofusa™ drug delivery platform. Importantly, bioavailability (BA) increased from 17% to 29%. [Table 1] [Table 2] [Table 3]
[0259] Figure 1 shows the location of key lymph nodes in rats examined in this experiment. Figures 3A-3D show a comparison of the in vivo biodistribution of etanercept when administered using Sofusa™ compared to intravenous and subcutaneous injection methods at both 12 and 36 hours. Using the Sofusa™ drug delivery platform resulted in a significant increase in active agent in the axillary and inguinal lymph nodes compared to either of the other administration methods. Such targeted administration may be able to significantly reduce metastasis of cancer that has begun to spread to lymph nodes. Figures 3A-3D show the difference in biodistribution of etanercept when administered using the Sofusa™ drug delivery platform compared to intravenous (Figures 3A and 3C) or subcutaneous (Figures 3B or 3D) administration. At both 12 and 36 hours, a much greater percentage of etanercept is located in the axillary and inguinal lymph nodes of rats when administered using the Sofusa™ drug delivery platform compared to the other administration methods. Figure 4 combines and summarizes the lymph node distribution data from Figures 3A-3D and clearly shows the striking change in the biodistribution pattern of etanercept when administered using the Sofusa™ drug delivery platform. In tumors exhibiting a high risk of metastasis, this significantly reduces the chances of cancer spreading, thereby improving patient outcomes.
[0260] Collagen-induced arthritis (CIA) model of rheumatoid arthritis (RA)
[0261] Figure 5A shows the timeline of induction, measurement and treatment of CIA animals. In detail, type II porcine collagen (Chondrex, Inc. catalog #20031) dissolved at a concentration of 2 mg / mL in 0.05 N acetic acid in sterile water was mixed with an equal volume of incomplete Freud's adjuvant (Freud's adjuvant 100 mg / mL) using homogenization (Omni International Homogenizer TH, Homogenizer Probe #32750) at 35,000 rpm. The mice were emulsified in 100 μL of emulsion (Chondrex, Inc. catalog #7002). 100 μL of emulsion was injected subcutaneously at the base of the tail on both sides for a first dose (day 0, 200 μL total emulsion) and again 7 days later for a booster dose on the right side only (day 7, 100 μL total emulsion). Hind paw swelling, which usually appears by day 14, was assessed by caliper measurements of the ankle width (side to side) and diagonal (anteroposterior) dimensions of the hind paws. For swelling assessment, the two measurements for each hind paw were multiplied and the percent change from baseline was calculated. These measurements and lymphatic imaging were performed on days 0, 7, 11, 13, and 18 during the early stages of CIA, prior to the onset of joint destruction. Four groups of animals were studied: (1) untreated (n=20), (2) treated with etanercept given SC (n=20, 1 mg in 100 μL), (3) treated with etanercept given ID (n=20, two doses of 0.5 mg in 50 μL), and (4) treated with etanercept given by Sofusa™ (n=18, one dose of 1 mg delivered in 100 μL).
[0262] Lymphatic pumping rate
[0263] Rats were anesthetized with isoflurane and hair was shaved prior to imaging. NIRF imaging of lymphatic vessels was then performed by ID injection of 10 μL of 625 μM ICG into the base of the rat tail and the dorsum of both right and left paws using a 31-gauge needle / syringe (BD#328438, Fisher Scientific). NIRF images were collected using a custom-built system that utilized illumination of the tissue surface with 785 nm light from a laser diode (85 mA and 80 mW, DL7140-201, Sanyo Electric Co., Ltd.), diffused to cover a circular area of approximately 8 cm in diameter. Fluorescence generated from ICG within the lymphatic vasculature was collected with an electron-multiplying charge-coupled device (EMCCD) (model 7827-0001, Princeton Instruments). Filter sets were used to eliminate backscattered and reflected excitation light. Images were acquired with V++ software (Total Turnkey Solutions, Sydney, Australia). The integration time for fluorescence images was 200 ms. For measurements of lymphatic propulsion frequency, 300–900 images were collected per side of the rat. Images were collected on or before day zero (when the first CIA injection was administered) and 11, 13, and 18 days after CIA induction.
[0264] result
[0265] As shown in Figures 5B-5G, administration of etanercept using the Sofusa™ drug delivery platform reduced joint swelling over time in an in vivo CIA RA model. Surprisingly, lymphatic pumping rate (i.e., the rate at which lymph moves through the lymphatic system) correlated with reduced joint swelling in the CIA RA rat model.
[0266] As shown in Figures 6 and 7A-7D, administration of etanercept via the Sofusa™ drug delivery platform significantly increased lymphatic pumping rate compared to untreated, ID and SC groups, which was shown to correlate with reduced joint swelling and improved joint function in the CIA RA rat model.
[0267] Univariate analysis on days 13 and 18 after induction of CIA showed (1) a statistically significant increase in lymphatic pumping in the hind paws of animals treated with SOFUSA™ and SC administration compared to untreated animals, and (2) a significant reduction in hind paw swelling in all treatment groups compared to untreated animals. Animals treated with SOFUSA™ showed a significant reduction in hind paw swelling on days 13 and 18 compared to SC treated animals.
[0268] Paired group comparisons using contrasts in an ANOVA model showed that no statistically significant increase in swelling was observed in animals treated with SOFUSA™ administration, while untreated animals and animals treated with SC and ID administration showed a significant increase in swelling and disease progression.
[0269] Results in the Yorkshire pig model
[0270] Importantly, the improved PK / PD profile initially observed in the rat model continued in the pig model. As shown in Figure 8, administration of etanercept using the Sofusa™ drug delivery platform in the pig model maintained serum concentrations at therapeutically effective concentrations at doses much lower than subcutaneous administration in the pig model. The use of much lower doses of etanercept has the potential to reduce side effects and associated potential adverse effects compared to other routes of administration.
[0271] Figures 9 and 10 and Table 4 show a comparison of the pharmacokinetic profiles of etanercept in a porcine model when administered intravenously, subcutaneously, and using the Sofusa™ drug delivery platform. AUC of etanercept 48 and bioavailability was comparable to that of intravenous administration and significantly higher than that of subcutaneous delivery. [Table 4]
[0272] Example 2 Tumor metastasis test
[0273] Female BALB / c mice (15-20 g) were inoculated with 20K 4T1-luc cells (mouse breast carcinoma) into the right mammary fat pad. On days 11, 15, 19, and 23 after inoculation, mice were treated with 10 mg / kg anti-mCTLA-4 monotherapy (clone 9H10 from BioXcell) administered using the Sofusa™ drug delivery platform at a flow rate of 100 μL / hr. Delivery of monotherapy was to the axillary lymph nodes ipsilateral to the tumor in rats. Tumor volumes were monitored periodically using calipers, and on day 30, animals were sacrificed and bioluminescence imaging was performed to determine the metastatic burden of each animal.
[0274] result
[0275] Figure 12 shows a graph of tumor volume over time for rats treated with anti-mCTLA-4 monotherapy using the Sofusa™ drug delivery platform compared to both IP-administered and untreated controls. As expected, the untreated control tumors were larger than those treated with anti-mCTLA-4 monotherapy. However, the tumor volumes of animals treated with Sofusa™ were significantly smaller than those treated with IP administration.
[0276] Additionally, extensive metastases were observed in all control animals (Sofusa™ administered vehicle only, N=4) as shown in Figure 11. In contrast, no metastases were observed in animals treated with anti-mCTLA-4 monotherapy (N=4), and tumors were significantly reduced in size or completely eliminated.
[0277] This description uses examples to disclose the subject matter herein, including the best mode, and to enable one of ordinary skill in the art to practice the subject matter of the present disclosure, including making and using any device or system, and performing any incorporated methods. The patentable scope of the present disclosure is defined by the claims, and may include other examples that occur to those of ordinary skill in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements that are insubstantial different from the literal language of the claims. The present invention provides, for example, the following items. (Item 1) 1. A method for administering a therapeutic agent to the lymphatic system of a patient, comprising: placing a first medical device including a plurality of microneedles on the patient's skin at a first location proximate a first position under the patient's skin, the first location proximate a lymphatic vessel and / or lymphatic capillary that drains into a right lymphatic trunk, the microneedles of the first medical device having a surface including a nanotopography; placing a second medical device comprising a plurality of microneedles on the patient's skin at a second location proximate a second location under the patient's skin, optionally wherein the first and second medical devices are the same device, the second location proximate a lymphatic vessel and / or lymph capillaries draining into the thoracic duct, and the microneedles of the second medical device have a surface comprising nanotopography; inserting the plurality of microneedles of the first medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the first location; inserting the plurality of microneedles of the second medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate the second location; and administering a first dose of the therapeutic agent to the first location via the microneedles of the first medical device and administering a second dose of the therapeutic agent to a second location via the microneedles of the second medical device. A method comprising: (Item 2) 2. The method of claim 1, wherein the administration of the first dose and the administration of the second dose are simultaneous. (Item 3) 3. The method of any one of items 1 or 2, wherein the administration of the first dose and the administration of the second dose overlap in time. (Item 4) 4. The method of any one of items 1 to 3, wherein the administration of the first dose and the administration of the second dose are sequential. (Item 5) 5. The method of any one of items 1 to 4, wherein the first and second medical devices are different devices. (Item 6) 5. The method of claim 4, wherein the first and second medical devices are the same device. (Item 7) 7. The method of any one of items 1 to 6, wherein administration of the doses cumulatively provides a therapeutically effective amount of the therapeutic agent. (Item 8) 8. The method of any one of items 1 to 7, wherein the first location and the second location are on different limbs of the patient. (Item 9) 9. The method of any one of items 1 to 8, wherein the first location and the second location are each independently proximate to a hand or a foot of the patient. (Item 10) 10. The method of any one of items 1 to 9, wherein one of the first location or the second location is on the patient's right arm or right leg and the other location is on the patient's left arm or left leg. (Item 11) placing a third medical device including a plurality of microneedles on the patient's skin at a third location proximate a third location under the patient's skin, the third location being proximate a lymphatic vessel and / or lymphatic capillary; inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate the third location; and Administering a third dose of the therapeutic agent via the third medical device. Further comprising: the third location is different from the first location and the second location; the third position is different from the first position and the second position; 11. The method according to any one of items 1 to 10. (Item 12) 12. The method of claim 11, wherein the first location, the second location and the third location are on different limbs of the patient. (Item 13) the first location, the second location, and the third location are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain different lymph nodes; 13. The method according to item 11 or 12, wherein the draining lymph nodes are selected from the group of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes. (Item 14) placing a fourth medical device including a plurality of microneedles on the patient's skin at a fourth location proximate a fourth location under the patient's skin, the fourth location being proximate a lymphatic vessel and / or lymphatic capillary; inserting the plurality of microneedles of the fourth medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the fourth location; and Administering a fourth dose of the therapeutic agent via the fourth medical device. Further comprising: the first location, the second location, the third location and the fourth location are on different limbs of the patient. 14. The method according to any one of items 11 to 13. (Item 15) the first dose and the second dose are administered simultaneously, and the third dose and the fourth dose are administered simultaneously; 15. The method of claim 14, wherein the administration start time of the first dose and the second dose is different from the administration start time of the third dose and the fourth dose, and there is a period of time between the administration start times of the doses. (Item 16) the third location drains into the right lymphatic trunk; the fourth location drains into the thoracic duct; 16. The method according to any one of items 14 or 15. (Item 17) the first location and the third location on the patient's skin are different from one another, and the first location and the third location are different from one another; 17. The method of claim 16, wherein the first location and the third location are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain different lymph nodes. (Item 18) the second location and the fourth location of the patient's skin are distinct from one another, and the second and fourth portions of the lymphatic system are distinct from one another; 20. The method of claim 17, wherein the second location and the fourth location are selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain different lymph nodes. (Item 19) 19. The method of any one of items 1 to 18, wherein the administration of the first dose of the therapeutic agent and the administration of the second dose of the therapeutic agent overlap in time. (Item 20) 1. A method for administering a therapeutic agent to the lymphatic system of a patient, comprising: placing a first medical device including a plurality of microneedles on the patient's skin at a first location proximate a first position under the patient's skin, the first location proximate a lymphatic vessel and / or lymphatic capillary that drains into a right lymphatic trunk, the microneedles of the first medical device having a surface including a nanotopography; placing a second medical device comprising a plurality of microneedles on the patient's skin at a second location proximate a second location under the patient's skin, the second location being proximate a lymphatic vessel and / or lymphatic capillaries draining into a thoracic duct, the microneedles of the second medical device having a surface comprising nanotopography, and optionally the first and second medical devices being the same medical device; inserting the plurality of microneedles of the first medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the first location; inserting the plurality of microneedles of the second medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the second location; administering a first dose of the therapeutic agent to the first location through the microneedle of the first medical device; and Administering a second dose of the therapeutic agent to the second location through the microneedle of the second medical device. Including, The method, wherein the administration start times of said first dose and said second dose are different and separated by a fixed time. (Item 21) 21. The method of claim 20, wherein the period of time is at least 4, 6, 8, 10, 12, 16, 24, 36, 48 or 72 hours. (Item 22) 22. The method of any one of items 20 or 21, wherein the first dose, the second dose, or the first and second doses together constitute a therapeutically effective dose. (Item 23) 23. The method of any one of items 20 to 22, wherein the first dose and the second dose are therapeutically effective doses. (Item 24) placing a third medical device comprising a plurality of microneedles on the patient's skin at a third location proximate a third location under the patient's skin, the third location being proximate a lymphatic vessel and / or lymphatic capillaries, the microneedles of the third medical device having a surface comprising nanotopography; inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate the third location; and administering a third dose of the therapeutic agent to the third location via the microneedle of the third medical device. Further comprising: The administration start times of the first dose, the second dose, and the third dose are separated by a fixed time, the first location, the second location and the third location are located on different limbs of the patient. The method according to items 20 to 23. (Item 25) placing a third medical device comprising a plurality of microneedles on the patient's skin at a third location proximate a third location under the patient's skin, the third location being proximate a lymphatic vessel and / or lymphatic capillaries, the microneedles of the third medical device having a surface comprising nanotopography; inserting the plurality of microneedles of the third medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is proximate the third location; and administering a third dose of the therapeutic agent to the third location via the microneedle of the third medical device. Further comprising: the administration start times of the first dose, the second dose and the effective dose are separated by a fixed time, the first location and the third location are different and selected such that the therapeutic agent is administered initially to regions of the lymphatic system that drain different lymph nodes; The method according to items 20 to 23. (Item 26) 26. The method of any one of items 24 or 25, wherein the first dose, the second dose, the third dose or a combination of any two or more thereof constitutes a therapeutically effective dose. (Item 27) 27. The method of any one of items 24 to 26, wherein the first dose, the second dose and the third dose are therapeutically effective doses. (Item 28) 28. The method of any of items 24 to 27, wherein the first location and the third location initially drain to different lymph nodes. (Item 29) placing a fourth medical device comprising a plurality of microneedles on the patient's skin at a fourth location proximate a fourth location under the patient's skin, the fourth location being proximate a lymphatic vessel and / or lymphatic capillary, the microneedles of the fourth medical device having a surface comprising nanotopography; inserting the plurality of microneedles of the fourth medical device into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the fourth location; and administering a fourth therapeutically effective dose of the therapeutic agent to the fourth location via the microneedles of the fourth medical device. Further comprising: The administration start times of the first dose, the second dose, the third dose and the fourth dose are separated by a fixed time, the lymphatic vessel and / or lymphatic capillaries at the third location drain into a right lymphatic trunk, and the lymphatic vessel and / or lymphatic capillaries at the fourth location drain into the thoracic duct; the first location and the third location are different and selected such that the therapeutic agent is administered initially to regions of the lymphatic system that drain different lymph nodes; the second location and the fourth location are different and selected such that the therapeutic agent is administered to regions of the lymphatic system that initially drain different lymph nodes. 29. The method according to any one of items 24 to 28. (Item 30) 30. The method of claim 29, wherein the first dose, the second dose, the third dose, the fourth dose, or a combination of any two or more thereof, constitutes a therapeutically effective dose. (Item 31) 31. The method of item 29 or 30, wherein the first dose, the second dose, the third dose and the fourth dose are therapeutically effective doses. (Item 32) 32. The method of any one of items 1 to 31, wherein the first and second locations effect delivery to lymphatic capillaries and / or lymphatic vessels that drain into different lymph nodes. (Item 33) 33. The method of any one of items 1 to 32, wherein the lymph nodes are selected from the group of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, extra-aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof. (Item 34) 34. The method of any one of the preceding claims, wherein the first location is a first arm and the second location is selected from an opposing leg or arm of the patient's body. (Item 35) 35. The method of any one of items 1 to 34, wherein the therapeutic agent is an immunosuppressant. (Item 36) 36. The method of any one of items 1 to 35, wherein the therapeutic agent is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, ustekinumab, rituximab, secukinumab, omalizumab, natalizumab, ixekizumab, obinutuzumab, rituximab / hyaluronidase human, or a biosimilar or bioequivalent of any of the foregoing. (Item 37) 37. The method of any one of items 1 to 36, wherein the therapeutic agent is an anti-CTLA-4 antibody. (Item 38) 1. A method for preventing or reducing metastasis of a cancer in a patient, comprising: Locating at least one lymph node of the patient that is interposed in the lymphatic system between the solid cancer tumor and the draining lymphatic system; placing a medical device comprising a plurality of microneedles on the patient's skin proximate to a first location under the patient's skin located between the intervening lymph node and the solid cancer tumor, the first location proximate to a lymphatic vessel and / or lymphatic capillary of the patient's lymphatic system, the microneedles having a surface comprising nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the first location; and administering to said first location via said plurality of microneedles a therapeutically effective amount of an anti-CTLA-4 antibody effective to prevent or reduce metastasis of said solid cancer tumor. A method comprising: (Item 39) 1. A method for preventing or reducing metastasis of a cancer in a patient, comprising: locating a solid cancer tumor in the patient and locating at least one lymph node in the patient that is interposed in the lymphatic system between the solid cancer tumor and a draining lymphatic system; placing a medical device comprising a plurality of microneedles on the patient's skin at a first location on the patient's skin proximate to lymphatic capillaries and / or lymphatic vessels draining to the intervening lymph nodes, the microneedles having a surface comprising a nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated; and administering, via said plurality of microneedles, a therapeutically effective amount of an anti-CTLA-4 antibody effective to prevent or reduce metastasis of cancer to said lymphatic capillaries and / or lymphatic vessels draining said intervening lymph nodes. A method comprising: (Item 40) 1. A method of treating cancer in a patient, comprising: placing a medical device comprising a plurality of microneedles on the patient's skin proximate to a first location beneath the patient's skin, the first location proximate to a lymphatic vessel and / or lymphatic capillary of the patient's lymphatic system, the microneedles having a surface comprising nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated and an end of at least one of the microneedles is adjacent to the first location; and administering an anti-CTLA-4 antibody to said first location through said plurality of microneedles, thereby treating said cancer. A method comprising: (Item 41) 41. The method of any one of items 38 to 40, wherein the cancer comprises a tumor. (Item 42) 42. The method of any one of items 38 to 41, wherein the medical device is positioned distal to the inflow trunk relative to the tumor. (Item 43) 43. The method of claim 38, wherein at least one lymph node of the patient is interposed in the lymphatic system between the tumor and a draining lymphatic system, and the first location is located between the interposed lymph node and the tumor. (Item 44) 44. The method of any one of items 38 to 43, wherein the medical device is positioned at a location on the patient's skin that has lymphatic capillaries and / or lymphatic vessels that drain directly to the intervening lymph node without first passing through any previous lymph nodes. (Item 45) 45. The method of any one of items 38 to 44, wherein the cancer is a head and neck cancer and the lymph nodes are selected from the group consisting of jugular lymph nodes, cervical lymph nodes, supraclavicular lymph nodes, and combinations thereof. (Item 46) 45. The method of any one of items 38 to 44, wherein the cancer is oral cavity cancer and the lymph nodes are selected from the group consisting of the jugular lymph node chain, the cervical lymph nodes, the supraclavicular lymph nodes, and combinations thereof. (Item 47) 45. The method of any one of items 38 to 44, wherein the cancer is a cancer of the pharynx and the lymph nodes are selected from the group consisting of the jugular lymph node chain, the cervical lymph nodes, the supraclavicular lymph nodes, and combinations thereof. (Item 48) 45. The method of any one of items 38 to 44, wherein the cancer is melanoma and the lymph nodes are selected from the group consisting of axillary lymph nodes, inguinal lymph nodes, jugular lymph nodes, cervical lymph nodes, supraclavicular lymph nodes, and combinations thereof. (Item 49) 45. The method of any one of items 38 to 44, wherein the cancer is breast cancer and the lymph nodes are selected from the group consisting of axillary lymph nodes, internal mammary lymph nodes, supraclavicular lymph nodes, and combinations thereof. (Item 50) 45. The method of any one of items 38 to 44, wherein the cancer is prostate cancer and the lymph nodes are selected from the group consisting of lumbar lymph nodes, inguinal lymph nodes, peritoneal lymph nodes, and combinations thereof. (Item 51) 45. The method of any one of items 38 to 44, wherein the cancer is in the patient's reproductive system, with the proviso that the cancer is not ovarian cancer, and the lymph nodes are selected from the group consisting of lumbar lymph nodes, inguinal lymph nodes, peritoneal lymph nodes, and combinations thereof. (Item 52) 52. The method of any one of items 38 to 51, wherein the anti-CTLA-4 antibody is imilimumab, a biosimilar thereof or a biological equivalent thereof. (Item 53) 1. A method for treating an inflammatory medical condition in a patient, comprising: locating at least one site of inflammation in the patient, the at least one site of inflammation comprising a lymphatic vessel, a lymphatic capillary, a lymph node, a lymphatic organ, or any combination thereof; locating a first location in the patient's lymphatic system upstream of the site of inflammation; placing a medical device including a plurality of microneedles on the patient's skin proximate to the first location, the microneedles having a surface including a nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated; and administering, via said plurality of microneedles, to said first location, a therapeutically effective amount of an immunosuppressant effective to treat said inflammatory medical condition. A method comprising: (Item 54) 54. The method of item 53, wherein said upstream location of the lymphatic system is a lymph node selected from the group consisting of lymph nodes found in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, periaortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolic lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes, and combinations thereof. (Item 55) 55. The method of any one of items 53 or 54, wherein the at least one inflammatory site of the patient is a joint or a psoriatic lesion. (Item 56) 56. The method of any one of items 53 to 55, wherein the at least one inflammatory site of the patient is at least one joint selected from the group consisting of ankle joints, knee joints, hip joints, shoulder joints, elbow joints, metacarpophalangeal joints of the hand, metatarsophalangeal joints of the foot, wrist joints, neck joints, and combinations thereof. (Item 57) 57. The method of any one of items 53 to 56, wherein the at least one inflammatory site in the patient is a psoriatic lesion. (Item 58) 58. The method of any one of items 53 to 57, wherein the inflammatory medical condition is selected from the group consisting of Behcet's disease, sarcoidosis, rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, non-infectious uveitis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and combinations thereof. (Item 59) 1. A method for reducing TNF-α levels in a patient, comprising: Locating a first location in the patient's lymphatic system; placing a medical device including a plurality of microneedles on the patient's skin adjacent to the first location, the microneedles having a surface including a nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated; and administering, via said plurality of microneedles, to said first location, a therapeutically effective amount of an immunosuppressant effective to reduce TNF-α levels in said patient. A method comprising: (Item 60) 60. The method of claim 59, wherein the first location is at least one lymph node of the patient. (Item 61) 1. A method for treating an inflammatory medical condition in a patient, comprising: locating at least one site of inflammation in said patient, comprising a lymph node, a lymphatic capillary, a lymphatic vessel, a lymphatic organ, or any combination thereof; placing a medical device including a plurality of microneedles on the patient's skin adjacent to a first location beneath the patient's skin, the first location being positioned to include selected lymphatic capillaries and / or lymphatic vessels that deliver lymph directly to the lymphatic system at the site of inflammation, the microneedles having a surface including a nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated; and administering, via said plurality of microneedles, to said selected lymphatic capillaries and / or lymphatic vessels of said patient, a therapeutically effective amount of an immunosuppressant effective to treat said inflammatory medical condition. A method comprising: (Item 62) 1. A method for treating an inflammatory medical condition in a patient, comprising: placing a medical device comprising a plurality of microneedles on the patient's skin adjacent to a first location beneath the patient's skin, the first location being located to include lymphatic capillaries and / or lymphatic vessels that deliver lymph directly to the lymphatic system, the microneedles having a surface comprising nanotopography; inserting the plurality of microneedles into the patient to a depth whereby at least the epithelium is penetrated; and administering an immunosuppressant to the lymphatic capillaries and / or lymphatic vessels of the patient via the plurality of microneedles, thereby treating the inflammatory medical condition. A method comprising: (Item 63) 63. The method of any one of items 53 to 62, wherein the first location is positioned to include a selected lymphatic capillary and / or lymphatic vessel that delivers lymph directly to the patient's lymphatic system at a site of inflammation, including a lymph node, a lymphatic capillary, a lymphatic vessel, a lymphatic organ, or any combination thereof. (Item 64) 64. The method of any one of items 53 to 63, wherein the selected lymphatic capillaries and / or lymphatic vessels are located distal to the patient's heart, relative to the site of inflammation. (Item 65) 65. The method of any one of items 53 to 64, wherein the at least one inflammatory site in the patient is a joint. (Item 66) 66. The method of any one of items 53 to 65, wherein the at least one inflammatory site of the patient is at least one joint selected from the group consisting of ankle joints, knee joints, hip joints, shoulder joints, elbow joints, metacarpophalangeal joints of the hand, metatarsophalangeal joints of the foot, wrist joints, neck joints and combinations thereof. (Item 67) 67. The method of any one of items 53 to 66, wherein the site of inflammation is the knee and the selected lymphatic capillaries and / or lymphatic vessels drain into a popliteal lymph node. (Item 68) 67. The method of any one of items 53 to 66, wherein the site of inflammation is a knee and, for the knee, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart. (Item 69) 67. The method of any one of items 53 to 66, wherein the site of inflammation is the neck and the selected lymphatic capillaries and / or lymphatic vessels drain into cervical lymph nodes. (Item 70) 67. The method of any one of items 53 to 66, wherein the site of inflammation is the neck and, relative to the neck, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart. (Item 71) 67. The method of any one of items 53 to 66, wherein the site of inflammation is the shoulder and the selected lymphatic capillaries and / or lymphatic vessels drain to thoracic lymph nodes, supraclavicular lymph nodes, axillary lymph nodes, or any combination thereof. (Item 72) 67. The method of any one of items 53 to 66, wherein the site of inflammation is a shoulder and, for the shoulder, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart. (Item 73) 67. The method of any one of items 53 to 66, wherein the site of inflammation is an elbow and the selected lymphatic capillaries and / or lymphatic vessels drain to medial epicondylar lymph nodes and / or brachial lymph nodes. (Item 74) 67. The method of any one of items 53 to 66, wherein the site of inflammation is an elbow and, relative to the elbow, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart. (Item 75) 67. The method of any one of items 53 to 66, wherein the site of inflammation is the hip joint and the selected lymphatic capillaries and / or lymphatic vessels drain to inguinal lymph nodes and / or pelvic lymph nodes. (Item 76) 67. The method of any one of items 53 to 66, wherein the site of inflammation is a hip joint and, relative to the hip joint, the selected lymphatic capillaries and / or lymphatic vessels are located distal to the heart. (Item 77) 67. The method of any one of items 53 to 66, wherein the site of inflammation is a hip joint and, relative to the hip joint, the selected lymphatic capillaries and / or lymphatic vessels are located proximate to the heart. (Item 78) 78. The method of any one of items 53 to 77, wherein the inflammatory medical condition is rheumatoid arthritis. (Item 79) 79. The method of any one of items 53 to 78, wherein the inflammatory site is a psoriatic lesion. (Item 80) 80. The method of claim 79, wherein the selected lymphatic capillaries share common lymphatic vessels and / or lymphatic capillaries immediately adjacent to and / or within the psoriatic lesion. (Item 81) 81. The method of item 79 or 80, wherein the medical device is positioned within the psoriatic lesion and / or at a location on the patient's skin that has lymphatic capillaries and / or lymphatic vessels that drain directly to the lymph node closest to the psoriatic lesion. (Item 82) the first medical device administers a first therapeutic agent to selected lymphatic capillaries and / or lymphatic vessels distal to the heart to the site of inflammation; 82. The method of claim 81, wherein the method further comprises administering via a second medical device a second therapeutic agent that is an immunosuppressant to selected lymphatic capillaries and / or lymphatic vessels proximate to the heart. (Item 83) 83. The method of item 82, wherein the antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof administered to the first location and the second therapeutic agent are the same or different. (Item 84) 84. The method of any one of items 53 to 83, wherein the immunosuppressant is a TNF-α inhibitor. (Item 85) 84. The method of any one of items 53 to 83, wherein the immunosuppressant is adalimumab, adalimumab-atto, certolizumab pegol, etanercept, etanercept-szzs, golimumab, infliximab, infliximab-dyyb, ustekinumab, rituximab, secukinumab, omalizumab, natalizumab, ixekizumab, obinutuzumab, rituximab / hyaluronidase human, or a biosimilar or bioequivalent of any of the foregoing. (Item 86) 84. The method according to any one of items 53 to 83, wherein the immunosuppressant is an antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof. (Item 87) 84. The method of any one of items 53 to 83, wherein the immunosuppressant is adalimumab or a biosimilar or biological equivalent thereof. (Item 88) 84. The method according to any one of items 53 to 83, wherein the immunosuppressant is etanercept or a biosimilar or biological equivalent thereof. (Item 89) 87. The method of item 86, wherein the antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof is adalimumab or a biosimilar or biological equivalent thereof. (Item 90) 87. The method of item 86, wherein the antibody that inhibits TNF-α or etanercept or a biosimilar or biological equivalent thereof is etanercept or a biosimilar or biological equivalent thereof. (Item 91) 91. The method of any one of items 53 to 90, wherein the first medical device is positioned within the site of inflammation and / or at a location on the patient's skin that has lymphatic capillaries and / or lymphatic vessels that drain directly to the lymph node closest to the site of inflammation. (Item 92) 92. The method of any one of items 53 to 91, wherein the selected lymphatic capillaries and / or lymphatic vessels are distal to the heart relative to the site of inflammation. (Item 93) 93. The method of any one of items 53 to 92, wherein the selected lymphatic capillaries and / or lymphatic vessels are in cardiac proximity to the site of inflammation. (Item 94) 94. The method of any one of items 1 to 93, wherein the patient is a mammal. (Item 95) 95. The method of any one of items 1 to 94, wherein the patient is a human. (Item 96) 96. The method of any one of the preceding claims, wherein the medical device is a Sofusa™ drug delivery platform. (Item 97) the medical device comprising a fluid delivery apparatus; 4. The fluid delivery device, a fluid dispensing assembly, a cap assembly coupled to a cartridge assembly, the cartridge assembly slidably coupled to a plenum assembly, and a mechanical controller assembly slidably coupled to the cartridge assembly; a collet assembly forming a housing for the fluid delivery device and slidably coupled to the fluid dispensing assembly; and a plurality of microneedles in fluid communication with the fluid distribution assembly, the plurality of microneedles having a surface including nanotopography, the plurality of microneedles being capable of penetrating the stratum corneum of a patient's skin and controllably delivering the therapeutic agent, the anti-CTLA-4 antibody or the immunosuppressant to a depth below the surface of the skin; 97. The method according to any one of items 1 to 96, comprising: (Item 98) 98. The method of any one of items 1 to 97, wherein the medical device delivers the therapeutic agent or the anti-CTLA-4 antibody or the immunosuppressant to a depth of about 50 μm to about 4000 μm, about 250 μm to about 2000 μm, or about 350 μm to about 1000 μm below the surface of the skin. (Item 99) 99. The method of any one of the preceding claims, wherein each of the microneedles of the medical device has a length of about 200 to about 800 μm, about 250 to about 750 μm, or about 300 to about 600 μm.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Micro-needle device for transdermal delivery of physiological active substances and the method of manufacturing the same
KR1020100113889A
Temporomandibular joint patch
US20030091619A1
Methods for intradermal delivery of therapeutics agents
US20050180952A1
Method for dispensing material into a drug delivery device
US20080009801A1
Intradermal cellular delivery using narrow gauge micro-cannula
US20080021439A1
